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1.1   Tablets:                                                    (Lachman L, Liberman H, 2000)                      
Definition:  
Tablets are tamper proof solid unit dosage forms containing medicament or 
mixture of medicaments and excipients compressed or molded into solid cylindrical 
shape having either flat or convex surfaces. 
1.1.1 Properties of tablets 
The attributes of an acceptable tablet are as follows: 
• The tablet must be sufficiently strong and resistant to shock, abrasion, should 
withstand handling during manufacturing, packing, shipping, and use. 
Hardness and friability tests measure this property. 
• Tablet must be uniform in weight and in drug content of the individual tablet. 
This is measured by the weight variation and content uniformity tests. 
• The drug content of the tablet must be bioavailable. This property is measured 
by the dissolution test. Accurate bioavailability can be obtained from the drug 
levels in the blood after its administration. 
• Tablets must be elegant in appearance, characteristic shape, colour and other 
markings necessary to identify the product. 
    1. INTRODUCTION   
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• Tablets must retain all these functional attributes which include drug 
stability and efficacy. 
1.2 Advantages and Disadvantages 
1.2.1. Advantages 
• Offers greatest capability of all oral dosage forms for the greatest dosage precision 
& least content uniformity.   
• High patient compliance. 
• Their cost is lowest of all dosage forms 
• One of the major advantages of tablet over capsules is that the tablet is essentially 
“tamper proof dosage form”. 
• Easiest and cheapest to packaging and shipment. 
• They are having best combined properties of chemical, mechanical and 
microbiological properties. 
• Accuracy of dose is maintained since tablet is a solid unit dosage forms. 
• Longer expiry period and minimum microbial spillage owing to lower moisture 
content. 
• Large scale manufacturing is feasible in comparison to other dosage forms. 
Therefore, economy can be achieved. 
• Organoleptic properties (colour taste, appearance, and odour) are improved by 
coating of the tablets. Product identification is easy and marketing done with the 
help of grooved punches and printing with edible ink. 
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• As a tablet is not a sterile dosage form, stringent environmental conditions are not 
required in the tablet department. 
1.2.2 Disadvantages 
• Some drugs resist compression owing to their amorphous nature & low density 
character. 
• Drugs with poor wetting, slow dissolution property, large dosages or any 
combination of these features may be difficult or impossible to formulate & 
manufacture as a tablet. 
• A major disadvantage of capsules over tablets is their higher cost. 
• It is difficult to convert a high dose poorly compressible API into a tablet of 
suitable size for human use. 
• Slow onset of action as compared to parentrals, liquid orals and capsules. 
• The amount of liquid drug (e.g., vitamin E, Simethicone) that can be trapped into 
a tablet is very less. 
• Difficult to swallow for kids, terminally ill and geriatric patients. 
• Patients undergoing radiotherapy cannot swallow tablet. 
1.3 Types and classes of tablets    (Lachman L, Liberman H, 2000)                      
Tablets are classified by their route of administration or function, by the type of 
drug delivery system they represent within that route, by their form and method of 
manufacture. 
Tablets ingested orally 
      1. Compressed tablets (CT) 
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      2.       Multiple compressed tablets (MCT) 
           a.   Layered tablets and Bi-layer tablets 
           b.   Compression coated tablets  
      3. Repeat action tablets 
      4. Delayed action and enteric coated tablets 
      5. Sugar and chocolate coated tablet 
      6. Film coated tablets 
      7. Air suspension coated tablets 
      8. Chewable tablets 
      9.         Dispersible tablets 
Tablets used in oral cavity 
      1. Buccal tablets 
      2. Sublingual tablets 
      3. Trouches, Lozenges and dental cones 
  Tablets used to prepare solution 
      1. Effervescent tablets 
      2. Dispensing tablets (DT) 
      3. Hypodermic tablets (HT) 
 4. Tablet triturates (TT) 
        The goal of any drug delivery system is to provide a therapeutic amount of 
drug in the proper site in the body to achieve promptly and then to maintain the 
desired   drug concentration that is, the drug delivery system should delivery system 
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should deliver drug at a rate dedicated by the needs of the body over a specified 
period of treatment. 
1.4 Oral drug delivery:                                (James Swarbrick et al., 2007) 
    This is the most widely utilized route of administration among all the routes 
that have been explored for systemic delivery of drugs via pharmaceutical products of 
different dosage form. Oral route is considered most natural, uncomplicated, 
convenient and safe due to its ease of administration, patient acceptance and cost 
effective manufacturing process.                            
 For many drug substances conventional immediate release formulations provide 
clinically effective therapy while maintaining the required balance of pharmacokinetic 
and pharmacodynamics profiles with an acceptable level of safety to the patient. 
                      Oral drug delivery is the most desirable and preferred method of 
administering therapeutic agents for their systemic effects. In addition, the oral 
medication is generally considered as the first avenue investigated in the discovery 
and development of new drug entities, pharmaceutical formulations, mainly because 
of patient acceptance and convenience in administration.  
                        Oral route of drug administration have wide acceptance up to 50-60% 
of total dosage forms. Solid dosage forms are popular because of ease of 
administration, accurate dosage, self-medication, pain avoidance and most 
importantly patient compliance. The most popular solid dosage forms are tablets and 
capsules. But the important drawback of these dosage forms is the difficulty to 
swallow.  
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                     Oral dosage form is the most popular route for drug therapy. Over 80% 
of the drugs formulated to produce systemic effects in the United States are produced 
as oral dosage forms. Compared to other oral dosage forms, tablets are the 
manufacturer‟s dosage form of choice because of their relatively low cost of 
manufacture, package. 
1.5 Current technologies in oral drug delivery: 
Over the last 3 decades, many novel oral drug therapeutic systems have been 
invented along with the appreciable development of drug delivery technology. 
Although these advanced drug delivery system are manufactured or fabricated in 
traditional pharmaceutical formulations, such as Tablets, Capsules, Sachets, 
Suspensions, Emulsions, and Solutions, they are superior to the conventional oral 
dosage forms in terms of their therapeutic efficacies, toxicities, and stabilities.  
Based on the desired therapeutic objectives, oral drug delivery system may be 
assorted into three categories:  
• Immediate-release preparations,  
• Controlled-release preparations and                                                                                                                                                  
 Targeted- release preparations.  
  1 .5.1 Immediate-Release Preparations:    (Syed Azeem et al., 2011) 
 These preparations are primarily intended to achieve faster onset of action for 
drugs such as analgesics, antipyretics, and coronary vasodilators. Other advantages 
include enhanced oral bioavailability through transmucosal delivery and pregastric 
absorption, convenience in drug administration to dysphasic patients, especially the 
elderly and bedridden, and new business opportunities. 
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Conventional IR formulations include fast disintegrating tablets and granules that 
use effervescent mixtures, such as sodium carbonate (or sodium bicarbonate) and 
citric acid (or tartaric acid), and superdisintegrants, such as sodium starch glycolate, 
croscarmellose sodium, and crospovidone. Current technologies in fast-dispersing 
dosage forms include modified tableting systems, floss or Shear form technology, 
which employs application of centrifugal force and controlled temperature, and 
freeze-drying.  
  1.5.2 Controlled-Release Preparations: 
  The currently employed CR technologies for oral drug delivery are diffusion-
controlled systems; solvent activated systems, and chemically controlled systems. 
Diffusion-controlled systems include monolithic and reservoir devices in which 
diffusion of the drug is the rate-limiting step, respectively, through a polymer matrix 
or a polymeric membrane. Solvent-activated systems may be either osmotically 
controlled or controlled by polymer swelling. Chemically controlled systems release 
drugs via polymeric degradation (surface or bulk matrix erosion) or cleavage of drug 
from a polymer chain. It is worth mentioning here that the so-called programmed-
release („„tailored-release‟‟) profile of a final control release product is rarely the 
outcome of a single pharmaceutical principle. Depending on the specific 
physicochemical properties of the drug in question and desired therapeutic objectives, 
different formulation and control release principles may be proportionally combined 
within the same dosage form. This task appears to be simpler when realized in terms 
of appropriate selection of polymers and recipients that incorporate desired principles. 
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 1.5.3 Targeted-Release Preparations:      [Leon Shargel et al., 2004]. 
Site-specific oral drug delivery requires spatial placement of a drug delivery 
device at a desired site within the GI tract. Although it is virtually possible to localize 
a device within each part of GI tract, the attainment of site-specific delivery in the oral 
cavity and the rectum is relatively easier than in the stomach and the small and large 
intestines. The latter requires consideration of both longitudinal and transverse aspects 
of GI constraints.  
1.6 Manufacturing Methods of tablets:                (F. A. Rowley, et al., 2005) 
There are four general methods of tablet preparation. 
• Direct compression                                                                                                                             
• Wet granulation method 
• Dry granulation method 
• Fluidized bed granulation 
In the tablet-pressing process, it is important that all ingredients be dry, powdered, 
and of uniform grain size as much as possible. The main guideline in manufacture is 
to ensure that the appropriate amount of active ingredient is equal in each tablet so 
ingredients should be well-mixed. Compressed tablets are exerted to great pressure in 
order to compact the material. If a sufficiently homogenous mix of the components 
cannot be obtained with simple mixing, the ingredients must be granulated prior to 
compression to assure an even distribution of the active compound in the final tablet. 
Two basic techniques are used to prepare powders for granulation into a tablet: wet 
granulation and dry granulation. Powders that can be mixed well do not require 
granulation and can be compressed into tablets through Direct Compression.  
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1.6.1 Direct Compression 
This method is used when a group of ingredients can be blended and placed in a tablet 
press to make a tablet without any of the ingredients having to be changed. This is not 
very common because many tablets have active pharmaceutical ingredients which will 
not allow for direct compression due to their concentration or the excipients used in 
formulation are not conducive to direct compression. 
Granulation is the process of collecting particles together by creating bonds between 
them. There are several different methods of granulation. The most popular, which is 
used by over 70% of formulation in tablet manufacture is wet granulation. Dry 
granulation is another method used to form granules. 
 1.6.2 Wet granulation 
Wet granulation is a process of using a liquid binder or adhesive to the powder 
mixture. The amount of liquid can be properly managed, and over wetting will cause 
the granules to be too hard and under wetting will cause them to be too soft and 
friable. Aqueous solutions have the advantage of being safer to deal with than 
solvents. 
• Procedure of Wet Granulation  
• Step 1: Weighing and Blending - the active ingredient, filler, disintegration 
agents, are weighed and mixed. 
Step 2: The wet granulate is prepared by adding the liquid binder/adhesive. 
Examples of binders/adhesives include aqueous preparations of cornstarch, natural 
gums such as acacia and cellulose derivatives such as methyl cellulose, CMC, gelatin, 
and povidone. Ingredients are placed within a granulator which helps ensure correct 
density of the composition. 
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• Step 3: Screening the damp mass into pellets or granules 
• Step 4: Drying the granulation 
• Step 5: Dry screening: After the granules are dried, pass through a screen 
of smaller size than the one used for the wet mass to select granules of 
uniform size to allow even fill in the die cavity 
• Step 6: Lubrication- A dry lubricant, anti adherent and glidants are added 
to the granules either by dusting over the spread-out granules or by 
blending with the granules. It reduces friction between the tablet and the 
walls of the die cavity. Anti adherent reduces sticking of the tablet to the 
die and punch. 
• Step7: liquid binder, but sometimes many actives are not compatible with 
water. Water mixed into the powder can form bonds between powder 
particles that are strong enough to lock them in together. However, once 
the water dries, the powders may fall apart and therefore might not be 
strong enough to create and hold a bond.  
 1.6.3 Dry granulation 
This process is used when the product needed to be granulated may be sensitive to 
moisture and heat. Dry granulation can be conducted on a press using slugging tooling 
or on a roller compactor commonly referred to as a chilsonator. Dry granulation 
equipment offers a wide range of pressure and roll types to attain proper densification. 
However, the process may require repeated compaction steps to attain the proper 
granule end point. It requires drugs or recipients with cohesive properties. 
• Some granular chemicals are suitable for direct compression (free flowing) 
e.g. potassium chloride. 
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• Tablets which have recipients with good flow characteristics and 
compressibility are used for direct compression of a variety of drugs. 
 1.6.4.Fluidized bed granulation 
It is a multiple step process performed in the same vessel to pre-heat, granulate and 
dry the powders. It is today a commonly used method in pharmaceuticals because it 
allows the individual company to more fully controls the powder preparation process. 
It requires only one piece of machinery that mixes all the powders and granules on a 
bed of air. 
1.7 EXCIPIENTS USED IN TABLETS:                     (Ramond C Rowe., 2006) 
   Excipients are inert substances used as diluents or vehicles for a drug. In the 
pharmaceutical industry it is a catch all terms which includes various sub-groups. 
Comprising of diluents or fillers, binders or adhesives, disintegrants, lubricants, 
glidants or flavours, fragrances and sweeteners. 
 All of these must meet certain criteria as follows:- 
• They must be physiological inert. 
• They must be acceptable to regulatory agencies. 
• They must be physiologically and chemically stable. 
• They must be free of any bacteria considered to be pathogenic or otherwise    
objectionable. 
• They must be not interference with the bioavailability of the drug. 
• They must be commercially available in the form and purity commensurate to 
pharmaceutical standards. 
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• Cost must be relatively inexpensive. 
                       To assure that   there is  no  excipient interferences with the utilization 
of the drug, the formulator must carefully and critically evaluate combinations of the 
drug with each of the contemplated excipients and must ascertain compliance of each 
ingredient with existing standards and regulations. 
                        The screening of drug-excipients and excipient-excipient interactions 
should be carried out routinely in preformulations studies . 
1.7.1. Fillers: (Diluents) 
               Tablet fillers of comprise a heterogeneous group of substances. Since they 
often comprise the bulk of the tablet, selection of a candidate from this group as a 
carrier for a drug is of prime importance.  
1.7.2. Binders: 
                Binders are the glue that holds powders together to form granules. They are 
the adhesives that are added to tablet formulations to provide the cohesiveness 
required for that bonding together of the granules under compaction to form a tablet. 
The quantity used and the method of application must be carefully regulated, since the 
tablet must remain intact when swallowed and then release its medicament. 
• Natural polymers such as starches or gums include acacia, tragacanth and 
gelatin. 
Synthetic polymers such as polyvinylpyrrolidine, methyl and ethyl cellulose and 
hydroxyl propyl cellulose. Commonly used binders are gelatin, glucose, methyl 
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• Cellulose, acacia, starch paste, povidone, alcohol, PVP in water, PVP in 
alcohol and sorbitol in water. 
1.7.3. Lubricants: 
                  Lubricants are used in tablet formulation to ease the ejection of the tablet 
from the die, to prevent sticking of tablets to the punches, and to prevent excessive 
wear on punches and dies. They function by interposing a film of low shear strength 
at the interface between the tablet and the die wall and the punch face.           
In selecting a lubricant, the following should be considered: 
• Lubricants markedly reduce the bonding properties of many excipients.  
• Over blending is one of the main causes of lubrication problems. Lubricants 
should be added last to the granulation and tumble-blended for not more than 
10 min. 
• Lubricant efficiency is a function of particle size; therefore, the finest grade 
available should be used and screened through a 100-300 mesh screen before 
use. 
• Examples of lubricants commonly used are magnesium stearic acid, talc, 
starch, magnesium stearate. 
1.7.4. Disintegrants: 
                   Disintegrants are used in tablet preparation to break the tablet faster. But 
some of the disintegrants are also having property of enhancing solubility of insoluble 
drug. 
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Examples 
• Crospovidone: Crospovidone is disintegrant, crospovidone also enhances 
solubility. 
• Sodium starch glycollate: sodium starch glycollate is widely used in oral 
pharmaceuticals and as a disintegrant in capsule. 
1.7.5. Glidants:   
                       Glidants are materials that improve the flow characteristics of granules 
by reducing the inter particulate friction. In proper amounts they also serve to assure 
smooth and uniform flow at all times.  
                      Many of the excipients commonly used in tablet formulations are 
especially applicable for use in chewable tablets due to their ability to provide the 
necessary properties of sweetness and chewabilty. In general; these fall into the sugar 
category, although a combination of excipients with artificial sweeteners may provide 
a satisfactory alternative. 
1.7.6 Miscellaneous 
1.7.6.1 Wetting Agents: 
                           Wetting Agents in tablet formulation aid water uptake and thereby 
enhancing disintegration and assisting in drug dissolution. Incorporation of anionic 
surfactant like Sodium Lauryl Sulphate (SLS) is known to enchance the dissolution. It 
has been established that SLS improves permeation of drug through biological 
membrane since it destroys the path through which drug has to pass and thus 
minimizing the path length for the drug to travel. Wetting agents are mainly added 
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when hydrophobic drug is to be formulated into tablet. SLS, Sodium disobutyl 
sulfosuccinate are used as wetting agent in tablet formulation. 
1.7.6.2 Dissolution Retardants: 
                    Dissolution Retardants are incorporated into tablet formulation only when 
controlled release of drug is required. Waxy materials like stearic acid and their esters 
can be used as dissolution retardants. 
1.7.6.3 Dissolution Enhancers: 
                    They are the agents that alter the molecular forces between ingredients to 
enchance the dissolution of solute in the solvent. Fructose, Povidone, Surfactants are 
used as dissolution enhancer. 
1.7.6.4 Adsorbents: 
                     Adsorbents are the agents that can retain large quantities of liquids. 
Therefore liquids like Vitamin E can be incorporated into tablets by addition of 
adsorbents. Most commonly used adsorbents in pharmaceuticals are anhydrous 
calcium phosphate, starch, magnesium carbonate, bentonite, kaolin, magnesium 
oxide. Generally the liquid to be adsorbed is first mixed with the adsorbent prior to 
incorporation into the formulation. 
1.7.6.5 Buffers: 
               Buffers are added to maintain a required pH since a change in pH may cause 
significant alteration in stability. Most commonly used buffering agent in tablet 
formulation includes sodium bicarbonate, calcium carbonate, and sodium citrate. 
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1.7.6.6 Antioxidants: 
               Antioxidants are added in tablet formulation to protect drug from 
undergoing oxidation. Antioxidants undergo oxidation in place of drug or they block 
the oxidation reaction or they act as synergys to other antioxidants. 
1.7.6.7 Chelating Agents: 
                    Chelating agents tend to form complexes with trace amount of heavy 
metals ions inactivating their catalytic activity in the oxidation of medicaments. 
Ethlenediamine tetra acetic acid and its salts, Dihydroxy Ethyl Glycerin, Citric Acid 
and Tartaric Acid are most commonly used chelators 
1.7.6.8 Flavours: 
                    Flavours are added to tablet formulation in order to make them enough in 
case of chewable tablet by improving the taste. Flavours are commonly used to 
improve the taste of chewable tablets as well as mouth dissolved tablets. Flavours are 
incorporated either as solids (spray dried flavours) or oils or aqueous (water soluble) 
flavours. 
1.7.6.9 Sweeteners: 
                 Sweeteners are added to tablet formulation to improve the taste of 
chewable tablets. Sweeteners used in tablet formulation- Mannitol, Lactose, Sucrose, 
Dextrose, Saccharin, Cyclamate, Aspartame etc.       
 1.8 TABLET COATING: 
Coated tablets are defined as the covered with one/more layers of mixtures of 
various substances such as natural waxes authorized colouring materials .Coating may 
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also contain active ingredient. Substances used for coating are usually applied as 
solution/suspension under condition where vehicle evaporates.  
Why Tablet Coating is required?  
A number of reasons can be suggested:  
•  The core contains a material which has a bitter taste in the mouth or 
has an unpleasant odour.  
•  Coating will protect the drug from the surroundings with a view to 
improve its stability.  
•  Coating will increase the ease by which a tablet can be ingested by the 
patient.  
•  Coating will develop the mechanical integrity; means coated products 
are more   resistant to mishandling (abrasion, attrition etc.)  
•  The core contains a substance which is incompatible in the presence of 
light and subject to atmospheric oxidation, i.e. a coating is added to 
improve stability.  
•  The core alone is inelegant.  
•  The active substance is coloured and migrates easily to stain hands 
and clothes.  
•  The coated tablets are packed on high-speed packaging machine. 
Coating reduces friction and increases packaging rate.  
•  Coating can modify the drug release profile, e.g., enteric coating, 
osmotic pump, pulsatile delivery.  
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1.8.1 Types of coating 
• Sugar coating 
• Film coating 
• Enteric coating  
• Controlled release coating 
• Specialized coating 
• Compressed coating 
• Electrostatic coating 
• Dip coating 
• Vacuum film coating 
1.8 .1.1 FILM COATING:                                 (Anand Shah et al., 2009) 
 Film coating is the process whereby a tablet, capsule, or pellet is surrounded 
by a thin layer of polymeric material. Film coated tablets are compressed tablets with 
a thin layer of suitable polymer capable of forming a skin like film over the tablet. 
The polymeric substance most commonly used are hydroxy propyl methyl cellulose, 
hydroxyl methyl cellulose, the film is usually collared and has the advantage over 
sugar coating in that it is more durable, less bulky, and less time consuming to apply. 
The film coating protects the medicament from the atmospheric effects. By its 
composition the coating is designed to rupture & expose the core tablet at the desired 
location within GIT.   
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Table1.1 Reason for film coating 
 Reasons for film coating: 
Appearance 
To change the colour, for branding purposes or other 
aesthetic reasons 
Stability 
To protect the active ingredient from moisture, light, and/or 
the acidic environment of the stomach 
Taste/odour  Masking 
To provide an easy to swallow tablet without the bitter taste 
of many actives 
Release characteristics 
Many film coating materials have functional properties 
which enable the delayed (enteric) release of dosage forms 
 
1.8.1.2 Process Description 
Film coating is a deposition of a thin layer of polymer surrounding the tablet core. 
Conventional pan equipments may be used but now a days more sophisticated 
equipments are employed to have high degree of automation of coating time. The 
polymer is solubilised into solvent, other additives like plasticizer &pigments are 
added. Resulting solution is sprayed on to a rotated tablet bed. The drying conditions 
cause removal of the solvent, giving thin deposition material around each tablet core. 
 
1.8.1.3 Process Details 
Usually spray process is employed in preparation of film coated tablet. Accelacota 
is the type of prototype of perforated cylindrical drum providing drying air capacity. 
Fluidized bed equipment has made considerable impact where tablets are moving in a 
stream of air passing through the perforated bottom of a cylindrical column with a 
smaller cylindrical insert the stream of cores is rising in the centre of device together 
with spray mist applied in the middle of the bottom. For fluidized coating very hard 
tablet hardness above 10 kg/cm
2
 has to be used. 
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1.8.1.4 Materials used in film coating: 
• Opaquent extenders 
• Miscellaneous coating solution components 
1.8.1.5 Used film formers: 
Hydroxyl propyl methyl cellulose (HPMC),Methyl hydroxyl ethyl cellulose 
(MHEC),Ethyl cellulose (EC),Hydroxyl propyl cellulose (HPC), sodium carboxyl 
methyl cellulose (CMC), Acrylate polymers, Povidone. 
Advantages: 
•    It is less time consuming technology. 
•    Not much labour is required. 
•    No adverse effect on Disintegration time of tablet. 
•    Production cost is low because material used for coating is cheap. 
•    Protects drug from atmospheric changes such as light, air, moist. 
•    Resist cracking, Chipping. 
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1.9   REGULATORY AFFAIRS 
       REGULATORY AFFAIRS is the link between the company and the 
regulatory agencies. 
It is also called as GOVERNMENT AFFAIRS. 
Regulatory Affairs is a comparatively new profession which has developed 
from the desire of governments to protect public health, by controlling the safety and 
efficacy of products in areas including pharmaceuticals, veterinary medicines, 
medical devices, cosmetics and complementary medicines. 
The companies responsible for the discovery, testing, manufacture and 
marketing of these products also want to ensure that they supply products that are safe 
and make a worthwhile contribution to public health and welfare. 
The Regulatory Affairs professional‟s job is to keep track of the ever- 
changing legislation in all the regions in which the company wishes to distribute its 
products .They also advice on the legal and scientific restrains and requirements, and 
collect, collate, and evaluate the scientific data that their research and development 
colleagues are generating. 
They give strategic and technical advice at the highest level in their 
companies, right from the beginning of the development of a product, making an 
important contribution both commercially and scientifically to the success of a 
development program of the company as a whole. 
                              REGULATORY AFFAIRS INTRODUCTION 
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The Regulatory Affairs department will take part in the development of the 
product marketing concepts and is usually required to approve packaging and 
advertising before it is used commercially. 
The Regulatory Affairs professionals help the company avoid problems 
caused by badly kept records, inappropriate scientific thinking or poor presentation of 
data. In most product areas where regulatory requirements are imposed, restrictions 
are also placed upon the claims and can be made for the product on labeling or in 
advertising. 
REGULATORY AFFAIRS professionals usually have responsibility for the 
following areas 
   1) Ensuring that their companies comply with all of the regulations and laws 
pertaining to their business. 
    2) Advising their companies on the regulatory aspects and climate that would affect 
proposed activities i.e. describing the “regulatory climate” around issues such as the 
promotion of prescription drugs. 
    3) Working with federal, state, and local regulatory agencies and personnel on 
specific issues affecting their business i.e. working with such agencies as the Food 
and Drug Administration or European Medicines Agency. 
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1.10 NSAID’S INTRODUCTION                        (H.P. Rang,M.M. Dale.,) 
Non-steroidal anti-inflammatory drugs (NSAIDS) are among the most widely 
used of all therapeutic agents worldwide. They are frequently prescribed for 
„rheumatic‟ musculoskeletal complaints and are often taken without prescription for 
minor aches and pains. 
1.10.1Pharmacological actions                              (Vane and Botting, 2001) 
  NSAIDS include a wide variety of different agents of different chemical 
classes. Most of the drugs have three major types of effects: 
 Anti-inflammatory effects 
 Analgesic effects of certain sorts of pain 
 Antipyretic effect: lowering of a raised temperature 
In general, all of these effects are related to the primary action of the drugs-
inhibition of arachidonate cyclooxygenase and thus inhibition of the production of 
prostaglandins and thromboxanes - though some aspects of the action of individual 
drugs may occur by different mechanism, in addition, some drugs have action other 
than those on inflammation. 
There are two types of cyclooxygenase enzyme, namely COX-1 and COX-
2.COX-1 is a constitutive enzyme expressed in most tissues, including blood platelets. 
It has a house-keeping role in the body being involved in tissue homeostatis.COX-2 is 
induced in inflammatory cells when they are activated, and the primary inflammatory 
                          NSAIDS INTRODUCTION 
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cytokines-interleukin-1 (IL-1) and tumour necrosis factor-α (TNF-α) are important in 
this regard. Thus COX-2 is responsible for the production of the prostanoid mediators 
of inflammation. 
It has become clear that the anti-inflammatory action of the NSAIDs is mainly 
related to their inhibition of COX-2 and that, when used as anti-inflammatory agents, 
their unwanted effects particularly those affecting the gastrointestinal tract-are largely 
a result of their inhibition of COX-1.Compounds with a selective action on COX-2 
are now in clinical use, and more in development. It is expected that these COX-2 
inhibitors could transform the approach to the treatment of inflammatory conditions. 
 Antipyretic effect           
    Normal body temperature is regulated by a centre in the hypothalamus that 
ensures a balance between heat loss and heat production. Fever occurs when there is a 
disturbance of this hypothalamic „thermostat‟, which leads to the set-point of body 
temperature being raised. NSAIDs reset the thermostat. Once there has a return to the 
normal set-point, the temperature regulating mechanisms then operate to reduce 
temperature. Normal temperature is not affected by NSAIDs. 
NSAIDs are thought to be antipyretic largely through inhibition of 
prostaglandin production in the hypothalamus. During an inflammatory reaction, 
bacterial endotoxins cause the release from macrophages of a pyrogen-IL-1.which 
stimulates the generation, in the hypothalamus, of E-type prostaglandins (PGEs) and 
these, in turn cause the elevation of the set-point for temperature.COX-2 may have a 
role here since it is induced by IL-1 in blood vessel endothelium in the hypothalamus. 
COX-3 may be implicated in fever. 
Study and Evaluate to Propose an Alternate API  Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 25 
 
There is some evidence that prostaglandins are not the only mediators of fever, hence 
NSAIDs may have an additional antipyretic effect by mechanisms as yet unknown. 
Analgesic effect                                                                                                                                          
   NSAIDs are mainly effective against pain associated with inflammation or 
tissue damage because they decrease production of the prostaglandins that sensitise no 
receptors to inflammatory mediators such as bradykinin. Therefore they are effective 
in arthritis, bursitis, pain of muscular and vascular orign, toothache, dysmenorrhoea, 
the pain of postpartum states and the pain of cancer metastases in bone-all conditions 
that are associated with increased prostaglandins synthesis.  In combination with 
opioids, they decrease   the pain and in some cases can reduce the requirements for 
opiods by as much as one third. Their ability to relieve headache may be related to the 
abrogation of the vasodilator effect of prostaglandins on the cerebral vasculature. 
There is some evidence that they have a central effect by an action mainly in the 
spinal cord.  
Anti-inflammatory Effect 
  There are many chemical mediators of the inflammatory and allergic 
response. Each facet of the response- vasodilation, increased vascular permeability, 
cell accumulation, etc.-can be produced by several different mechanisms. 
Furthermore, different mediators may be of particular importance in different 
inflammatory and allergic conditions and some mediators have complex interactions 
with others, for example small amounts of nitric oxide (NO)stimulates 
cyclooxygenase activity, while large amounts inhibit it. 
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Drugs such as the NSAIDs reduce mainly those components of the inflammatory and 
immune response in which the products of COX-2 action play a significant part 
namely 
 Vasodilation 
 Oedema 
 1.10.2 Mechanism of Action 
The main action of NSAIDs is, as stated above, inhibition of arachidonic acid- 
metabolising activity of COX. The cyclooxygenase enzymes are bifunctional, having 
two distinct activities: the main action, which gives PGG2. And a peroxidise action, 
which converts PGG2 to PGH2. Both COX-1 and COX-2 inhibitors inhibit only the 
main cyclooxygenase reaction, both COX-1 and COX-2 are associated with the 
membrane and each consists of a long channel with a bend at the end, the channel 
being wider in COX-2. The opening of the channel is largely hydrophobic. 
Arachidonic acid enters, is twisted round the bend and has two oxygen‟s inserted and 
a free radical extracted, resulting in the five carbon ring characteristic of 
prostaglandins.COX-1 inhibition, in general, is instantaneous and competitively 
reversible.COX-2 inhibition is time dependent, i.e. its effect increases with time. 
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Figure.1.1 Mechanism of prostaglandins 
1.10.3 CLASSIFICATION OF NSAIDs 
1) COX-1 SELECTIVE INHIBITORS  
    - Acetylsalicylic acid at low dosage  
2) NON SELECTIVE COX INHIBITORS  
    - Acetylsalicylic acid at high   dosage  
    - Diclofenac 
    - Ibuprofen 
    - Ketoprofen  
    - Flurbiprofen 
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    - Indomethacin 
    - Piroxicam 
    - Naproxen  
3) MORE COX-2 SELECTIVE INHIBITORS  
    - Nimusulide 
   - Etodolak 
    -Meloxicam 
   - Nabumeton 
4) COX-2 SELECTIVE INHIBITORS  
    - Celecoxib 
    - Etorcoxib 
    - Valdecoxib  
1.10.4 ANTI-INFLAMMATORY EFFECTS OF NSAIDs 
 This effect of NSAIDs is due to the inhibition   of the enzyme COX, 
which converts arachidonic acid to prostaglandins, TXA2 and prostacyclin. 
Acetylsalicylic acid irreversibly inactivates COX-1 and COX-2 by acetylation of a 
specific serine residue.  
Other NSAIDs reversibly inhibit COX-1 and COX-2  
Additional anti-inflammatory mechanism may include: 
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- Interference with the potentiative action of other mediators of inflammation – 
bradykinin, histamine, serotonin  
- Modulation of T-cell function 
- Stabilization of lysosomal membranes 
- Inhibition of chemotaxis  
ANALGESIC EFFECT OF NSAIDS 
 This effect of NSAIDs is thought to be related to the peripheral 
inhibition of prostaglandin production, but it may also be due to the inhibition of pain 
stimuli at a subcortical site.  
NDAIDs prevent the potentiating action of prostaglandins on endogenous mediators  
of peripheral nerve stimulation ( e.g  bradykinin )  
   ANTIPYRETIC EFFECT OF NSAIDS 
 This effect is believed to be related to inhibition of the interleukin-1 
and interleukin-6 induced production of prostaglandins in the hypothalmus and the 
resetting, of the termo regulatory system, leading to vasodilation and increased heat 
loss.  
  
 
 
AIM &     
      OBJECTIVES...  
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Naproxen sodium (NSAIDS) is an FDA Approved prodrug for clinical use for 
the treatment of rheumatic musculo skeletal pains, acute gout and other minor pains 
either alone or in combination with other NSAIDS drugs. 
 Naproxen sodium is absorbed rapidly following oral administration producing 
peak plasma concentration within 1-2 hour with 95% bioavailability. 
Elimination half life is 12-17 hours. 
 It is usually administered in a dose of 220mg twice daily in order to maintain 
effective concentration. And the main dose related adverse effect is 
gastrointestinal disturbance, with increase in concentrations. 
 The drug has longer half life of 12-17 hours. Hence it is suitable for immediate 
release preparations. 
 Immediate release drug delivery systems for oral dosing are effective in 
achieving optimal therapy for the drugs that have longer half life. 
 These preparations were able to release immediately with quicker on set of 
action and without dose dumping problem by incorporating super disintegrants 
like sodium starch glycolate. 
 So the present work involves use of immediate release system for   Naproxen 
sodium  by incorporating super disintegrants will ensure the drug  to release 
the medicament immediately  for quicker on set of action which will increase 
the patient compliance. 
 Naproxen sodium was been formulated and marketed using the API of 
approved vendor i. e, REDDY‟S LTD by the GRANULES INDIA LTD. 
       2. AIM AND OBJECTIVE 
Study and Evaluate to Propose An Alternate API  Aim and Objective 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 31 
 
 As the approved API from REDDY‟S was not sufficient due to much demand 
for the drug Naproxen sodium in marketing field. 
 An alternate vendor i. e, CHARIOTEER was proposed. 
 According to regulatory point of view an alternate vendor for Active 
pharmaceutical ingredient can be approved if the specification standards and 
dissolution profile was same as compared with that of the already approved 
API according to the Alternate vendor guideline. 
 Hence the comparison for both the specification standards and percentage drug 
release was done for approved vendor (REDDY‟S) and alternate vendor 
(CHARIOTEER).  
2.1 Objectives: 
 To evaluate the requirements to propose an alternate Active Pharmaceutical 
         Ingredient source for an approved drug product. 
 Comparison of specification standards of both approved and alternate API 
source. 
 Comparison of dissolution profiles for both approved and alternate API 
source.  
 The objective of the present study is to compare both the API‟S i.e approved 
vendor (REDDY‟S) and alternate vendor (CHARIOTEER‟S) and to approve 
the alternate vendor as equivalent to that of approved vendor. 
 To formulate and evaluate Naproxen sodium immediate release Tablet of 
both the API‟S i.e. of both approved vendor (REDDY‟S) and alternate vendor 
(CHARIOTEER‟S). 
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 To study the effect of different super disintegrants on drug release behaviour 
of the polymer. 
 Based on the Pre and post formulation parameters characteristics the 
formulation for both the API‟S was carried out and short term stability studies 
were performed as per ICH guidelines. 
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The present work was carried out to evaluate the requirements to propose an 
alternate Active Pharmaceutical Ingredient source for an approved drug product. 
The approved API source for the drug product is REDDY‟S LTD and the alternate 
API source is Zhejiang charioteer. 
Scheme of work Listed as Follows: 
          Literature review 
          Selection of drug 
          Overview of manufacturing of drug substances (approved vendor  versus 
vendor) 
         Certificate of Analysis for finished   drug product. 
         Comparison of specification standards of both approved and alternate 
API source. 
        Comparison of dissolution profiles for both approved and alternate API 
source.  
      Tests performed for overview of standards. 
 Performing the tests according to specification standards 
   a) Solubility test 
      3. PLAN OF WORK 
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    b) Identification by IR 
    c) Specific optical rotation 
    d) Melting point 
    e) Loss on drying 
    f) Heavy metals 
    g) Related substances by HPLC 
    h) Partice size 
     e) Bulk Density 
 Evaluation of blend characteristics of prepared granules from both the API‟S 
(pre compression parameters) 
     a) Angle of repose 
     b) Determination of Bulk density  
     c) Determination of Tapped density 
     d) Sieve Analysis 
     e) Moisture content 
 Evaluation of physical parameters of Naproxen sodium (post compression 
parameters) 
      a) Disintegration 
        b) Friability 
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        c) Thickness 
        d) Hardness 
        e) Weight variation 
 Evaluation of dissolution profiles for Naproxen sodium   tablet obtained from 
both the API‟S.  
 STABILITY STUDY 
 RESULTS AND DISCUSSION 
 CONCLUSION 
 BIBLIOGRAPHY                         
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Pakhuri Mehta.,et al., (2012) had developed and undergone validation of 
related substances method by HPLC for analysis of Naproxen tablet formulations. A 
simple, selective, rapid, and precise and isocratic reversed phase high pressure liquid 
chromatography was been used, mobile phase acetonitrile and Ammonium acetate 
buffer Ph3.8 in ratio 550:450v/v. The detection and quantification limits were 0.13 
and 0.25µg/ml respectively. Statistical analysis proved the method was precise, 
reproducible selective, specific, and accurate for analysis of Naproxen and its 
impurities. The wide linearity range, short retention time, and simple mobile phase 
showed that the method is suitable for routine quantification of impurities in 
Naproxen in pharmaceutical dosage forms with high precision and accuracy. 
Deepali Avinash Meher. (2011) had formulated and developed the fast 
disintegrating Naproxen tablets using simplex lattice design. The aim of present work 
was done to show the effect of various super disintegrants on the disintegration time 
and in vitro drug release rate. In this study, an attempt had been made to prepare fast 
disintegrating tablets. The sodium starch glycolate, cross carmellose and povidone 
were used in different concentrations according to simplex lattice design. The tablets 
were evaluated for diameter, thickness, hardness, disintegration time and in vitro 
dissolution studies. Disintegration time of all the formulations showed less than 88 
seconds. Formulations containing cross carmellose sodium and povidone showed 
fastest disintegration than formulations containing sodium starch glycolate. 
   4. LITERATURE REVIEW 
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Neha Vishal Gandhi.,et al., (2011) Formulated and evaluated orodispersible 
tablets of Naproxen sodium. Naproxen sodium is an analgesic NSAID used for the 
treatment of pain, inflammation, rheumatoid arthritis, juvenile arthritis, gout. Present 
investigation was undertaken with a view to develop orodispersible tablet of 
Naproxen sodium which offers quick onset of action of drug and minimise the 
problem of gastric discomfort. In this study the tablets were prepared by direct 
compression method using super disintegrants e.g sodium starch glycolate, 
croscaramellose and povidone in different concentrations. The tablets were evaluated 
and results were compared, povidone was found to be the most efficacious 
superdisintegrants to formulate orodispersible tablets. 
Rangasamy Manivannan.,et al., (2010) had formulated and evaluated 
Naproxen sodium tablets USP. The objective of the present study was to develop a 
pharmaceutically stable and robust formulation of Naproxen sodium 220 mg 
compared with innovator. The tablets were   prepared   by using wet granulation 
technique. Several trails formulations i.e., from F1-10 were taken to optimise and 
develop a robust formulation. The prepared tablets were evaluated for weight 
variation, hardness, thickness, disintegration, in-vitro drug release and stability 
studies. 
Saravana Kumar K.,et al., (2012) had formulated and evaluated Naproxen 
sodium –loaded Chitosan microsphers. The chitosan based microsphers have been 
studied as controlled release to deliver Naproxen sodium in gastrointestinal tract. 
Mucoadhesive microsphers were prepared by emulsification solvent evaporation 
method by treating with tween-80 as surfactant, glutaraldehyde solutions as cross-
linker. Upon cross inking the resulting microsphers were found to be more efficient 
for prolonged drug release. The release of the drug was controlled by the mechanism 
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of the dissolution of NS in the dissolution medium and the diffusion of NS through 
the mucoadhesive microsphers. 
Vinay Wamorkar.,et al., (2011) had validated spectroscopic method for the 
estimation of Naproxen from tablet formulation. The present research work discusses 
the development of uv -spectroscopic method for the estimation of Naproxen. The 
optimum conditions for the analysis of the drug were established. The maximum 
wavelength was found to be 273nm. All calibrations curves show a linear relationship 
between the absorbance and concentration with coefficient of correlation 
0.999.Standard errors in case of recovery studies was satisfactorily low and allow 
estimation Naproxen in concentration range in the assay of bulk drugs and tablets. 
The sample solution was stable upto 36 hours. It is thus concluded that the proposed 
method is new, simple, cost-effective, safe, accurate, precise and environment 
friendly. 
Patil C.,et al., (2007) Formulated the oral tablets of Naproxen using guargum 
alone in combination with other polymers. Tablets were prepared by wet granulation 
using guargum, xanthian, methyl cellulose CAP as a polymer containing 100 mg of 
Naproxen. 
Hawkey Lancet.,et al ., (1999) In this studies  Hawkey revealed that the main 
anti-inflammatory agents are the glucocorticoids and the non steiordal anti 
inflammatory drugs (NSAIDs).The NSAIDS are dealt with below and, in dealing with 
them we describe the pharmacological actions common to all of them, their 
mechanism of action and unwanted effects.  
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F A Khan.,et al.,(2011) had validated for simultaneous determination of 
Naproxen and Pantoprazole sodium in capsule dosage form by RP-HPTLC. A simple 
sensitive and reliable spectroscopic method for the estimation of Naproxen and 
Patoprozole sodium in combined dosage form has been attempted. The analyte were 
resolved using MeOH: KH2PO4 buffer at a flow rate of 1.0 ml/min, on Thermo 
separation product quaternary gradient HPLC pump spectra containing of UV-1000 
UV visible detector with data Ace software and Prontosil C18 46 (id) 250 mm. The 
method gave good resolution and suitable retention time. The standard and sample 
solution of NAP and PAN were prepared in mobile phase. The detection was carried 
out at 275 nm the selection of the wave length was based on λ max. This system gave 
good resolution and optimum retention time with appropriate tailing factor(less 
than2). 
Padmanabh Deshpande.,et al., (2012) had validated method development for 
the estimation of Naproxen sodium as bulk drug in tablet dosage form by HPTLC. 
The present work describes as simple, precise and accurate HPTLC method. The 
chromatographic development was carried out on precoated silica gel 60 F254 
aluminium plates using mixture of toluene : ethyl acetate: acetic acid (7:5:1.5:1 v/v/v) 
as mobile phase and densinometric evaluation of band was carried out at 230 nm  
Camag TLC Scanner. The method was also evaluated by the assay of commercially 
available tablets. The % assay was found to be 99.34 % ± 0.146.The proposed method 
can analysis ten or more formulations units simultaneously on a single plate and 
provides cost-effective quality control tool for routine analysis of Naproxen sodium as 
bulk drug and in tablet formulation. 
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Syeda kulsum.,et al. (2011) had undergone the spectrometric methods for the 
determination of Naproxen sodium in pure and pharmaceutical dosage forms. Two 
visible spectrophotometric methods have been developed for the determination of 
Naproxen sodium either in pure form or in their pharmaceutical formulations. The 
developed methods are based on reaction of Naproxen with phenol red and 
bromocresol green. Their absorption maximum was found to be at 422nm, and Beer‟s 
law was obeyed in concentration ranges of 60-80µg/ml and 120-160µg/ml. The 
colours were found   to be stable for 4 hours. The proposed methods were successfully 
applied for determination of Naproxen in their pharmaceutical formulations. 
 Palavai Sripal Reddy.,et al., (2010)  had undergone studies on Impurities 
profiling method and degradation studies for sumatriptan succinate in sumatriptan 
succinate and Naproxen sodium tablets. A simple, sensitive, and precise high 
performance liquid chromatographic method for the impurities profiling of 
sumatriptan succinate in sumatriptan and Naproxen tablets had been developed, 
validated and used for determining impurities. The impurities were well separated by 
the gradient program using 0.05M Phosphate buffer (pH 3.0), acetonitrile and 
methanol at a flow rate of 1.0m/lmin-1 with detection wavelength at 225 nm. The 
developed method was found to be specific, precise, accurate and robust. LOQ values 
for all the known impurities were below reporting thresholds. 
   Seren Kayiran.,et al., (2010) had undergone studies on determination of 
Naproxen sodium from poly (lactide-co-glycolide) corneal scaffolds. Efficient 
chromatographic separation was achieved on a reverse phase column with the mobile 
phase consisting of methanol and acetate buffer (pH5.1) at a flow rate of ml/min by 
using fluorescence detector at 254 nm/352nm.The developed HPLC method was 
successfully applied to quantitate NS in PLGA. 
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M Harris Shoaib.,et al., (2011) had developed and evaluated Naproxen 
sodium effervescent tablets. The present study focuses on developing a  new, simple, 
cost effective formulation of Naproxen sodium using direct compression method. 
Nine different trial formulations were designed and evaluated. Tablets took 4 min and 
36 sec  to disintegrate. Dissolution was observed within 15 min. Stability studies were 
also found to be stable, such formulations increases patient compliance and have 
possibly improved bioavailability. 
Harun O Rashid.,et al., (2009) had designed and formulated Naproxen 
sustained release tablet matrix from Methocel K 15M CR and Methocel K 100M CR. 
The tablets were prepared by wet granulation method along with hydrophilic matrix 
materials. The granules were evaluated for angle of repose, drug content. Tablets were 
subjected to thickness, hardness, friability and in-vitro release at pH 7.4 .All 
formulations showed first order release kinetics. The matrix tablets of Naproxen using 
HPMC controls the drug release effectively for 24 hrs, hence the formulation can be 
considered as once daily sustained release tablets of Naproxen in order to improve 
patient compliance. 
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Name:                      Naproxen sodium 
Type:                        Small molecule 
Description:             An anti-inflammatory agent with analgesic and anti pyretic 
                                Properties. Both the acid and its sodium salt are used in the 
                                treatment of rheumatoid arthritis, musculoskletal disorders, 
                                and acute gout. 
State:                       Solid  
Structure:  
       
 
 
 
Synonym:             ALEVE 
                              ANAPROX 
                               EQUIPROXE 
                              Ec-naproSYN 
 
 
       5.1 DRUG PROFILE 
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BrandNames:             
   Naixan 
                         Naprius 
                         Naprux 
                         Naprium 
                         Niaxan 
                         Nycoprene 
                         Proxine 
                        Veradol 
Category  :       Cyclo oxygenase Inhibitors 
                        Gout Suppressant 
CAS. NO:       2204-53-1 
Weight     :        230.259 
Chemical   
Formula    :       C14H13O3Na 
IUPAC 
Name        :      2-(6-methoxynaphthalene-2-yl) propanoic acid 
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Solubility             :     Soluble in water, methanol, sparingly soluble in 
                                  alcohol, very slightly in acetone, and practically  
                                  insoluble in chloroform and toluene. 
Melting Point        :     152-157º C 
Taste and odour   :    Tasteless, odourless 
Absorption           :     Absorbed through GI tract 
Protein Binding     :      99.0% 
Half life               :     12-17 hours 
Bioavailibility     :       95.0% 
Mechanism         : 
 
 
 
 
 
                                    Figure 5.1 Mechanism of Action.  
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Indication         : 
  It is a non steroidal anti inflammatory drug (NSAID) with analgesic and 
antipyretic properties, for the treatment of rheumatoid arthritis, ankylosing 
spondylytis and acute gout. 
Pharmacokinetic Nature of Naproxen sodium 
Absorption: 
 Naproxen itself is rapidly and completely absorbed from the GI tract. 
An in-vivo bioavailability of 95% although Naproxen is well absorbed, the sodium 
salt form is more rapidly absorbed resulting in higher peak plasma levels. Food causes 
slight decrease in the rate of absorption. 
Distribution: 
   Naproxen has a volume of distribution of 0.16 l/kg. At therapeutic levels 
naproxen is greater than 99% albumin bound. At doses of naproxen greater than 
500mg/day there is less than proportional increase in plasma levels due to an increase 
in clearance caused by saturation of plasma protein binding at higher doses(average  
steady state concentration) 36.5,49.2 and 56.4mg/l, the concentration of unbound 
Naproxen continues to increase proportionally to dose.       
 Metabolism: 
 Naproxen is extensively metabolized to 6-O –desmethyl naproxen, and both 
parent and metabolites donot induce metabolizing enzymes. 
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Elimination: 
                The clearance of naproxen is 0.13ml/min/kg. Approximately 95%of the 
naproxen from any dose is excreted in the urine, primarily as naproxen (less than 1%), 
6-0-desmethyl naproxen (less than 1%)or their conjugates(66% to 92%).The plasma 
half life of the naproxen anion in humans ranges from 12 to 17 hours. The 
corresponding half lives of both naproxen‟s metabolites and conjugates are shorter 
than 12 hours, and their rates of excretion have been found to coincide closely with 
the rate of naproxen disappearance from the plasma. In patients with renal failure 
metabolites may accumulate.  
Drug Interactions: 
         Cyclosporine   :       Monitor for nephrotoxicity 
          Methotrexate   :       The NSAID, naproxen, may decrease the renal excretion of  
                                          methotrexate, increased risk of methotrexate toxicity. 
        Warfarin          :   The antiplatelet effects of naproxen may increase the   bleeding  
                                     risk associated  with warfarin.                            
Food Interactions: 
                                        Avoid alcohol 
                                        Take with a full glass of water 
                                        Take with food. 
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Side Effects             
     Gastro intestinal 
Constipation, Heart burn, Nausea, Diarrhea, Abdominal pain. 
     Central Nervous System 
  Headache, Dizziness, Vertigo. 
     Dermatologic 
 Itching, Skin eruptions, Sweating, Purpura. 
     Special Senses 
   Tinnitus, Hearing disturbances, Visual disturbances. 
    Cardiovascular 
  Edema, Dyspnea, Palpitation 
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       5.2.1 MICROCRYSTALLINE CELLULOSE     (Raymond C Rowe et al., 
2009) 
1. Nonproprietary names: 
BP:          Microcrystalline Cellulose 
JP:            Microcrystalline Cellulose 
Ph Eur:     Cellulose, Microcrystalline 
USP-NF:  Microcrystalline Cellulose 
2. Synonyms: 
                  Avicel PH,  Celex, cellulose gel, Celphere, Ceolus, Crystalline cellulose, 
E460, Emcocel, Fibrocel, Pharmacel, Tabulose, Vivapur. 
 3. Chemical Name: Cellulose  
 4. Empirical Formula & Molecular Weight: (C6H10O5)n  :   36,000 
 5.  Structural Formula: 
 
 
 
 
 
 
 
 
                  
 
 
  5.2 EXCIPIENT PROFILE 
       MICROCRYSTALLINE CELLULOSE 
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6. Functional Category: 
Adsorbent, suspending agent, tablet and Capsule diluents, tablet disintegrant. 
7. Applications in Pharmaceutical Formulation or Technology:      
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations .Microcrystalline cellulose is 
also used in cosmetics and food products. 
                           Table 5.1: Uses of Microcrystalline cellulose 
Use Concentration (%) 
Adsorbent 20-90 
Anti-adherent 5-20 
Capsule binder/diluents 20-90 
Tablet disintegrant 5-15 
Tablet binder/diluents 20-90 
8. DESCRIPTION:  
 Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles. 
9. Typical Properties: 
Angle of repose: 34.4° 
 Density (bulk)   : 0.32 g/cm
3
  
Density (tapped) : 0.45 g/cm
3
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Density (true)      : 1.512-1.668 g/cm
3
                 
Table 5.2: Properties of selected commercially available grades of                             
microcrystalline cellulose. 
Grade Nominal mean particle size 
Avicel PH-101 50 
Avicel PH-102 100 
Avicel PH-103 50 
Avicel PH-105 20 
 
10. Stability and Storage Conditions: 
Microcrystalline cellulose is a stable, though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry, place. 
11. Incompatibilities: 
Incompatible with strong oxidizing agents.   
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 5.2.2   Sodium Starch Glycolate (SSG) 
1. Synonyms:  
  Explotab, Primogel, Vivastar Carboxymethyl starch, sodium salt. 
2. Chemical Name: 
Sodium carboxymethyl starch. 
3. Structure: 
 
 
 
 
4. Description:  
  It is a white or almost white free-flowing very hygroscopic powder. The PhEur 
states that when examined under a microscope it is seen to consist of: granules 
irregularly shaped, ovoid or pear-shaped, 30–100 mm in size, or rounded,10–35 mm 
in size, compound granules consisting of 2–4 components occur occasionally; the 
granules have an eccentric hilum and clearly visible concentric striations. Between 
crossed nicol prisms, the granules show a distinct black cross intersecting at the 
hilum, small crystals are visible at the surface of the granules. The granules how 
considerable swelling in contact with water. 
 
 
 
 
 
        SODIUM STARCH GLYCOLATE 
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5. Functional Category:  
  Tablet and capsule disintegrate. 
6. Solubility:  
 Practically insoluble in water and insoluble in most organic solvents. 
7. Incompatibilities:  
Sodium starch glycolate is incompatible with ascorbic acid. 
8. Stability and Storage Conditions:  
              Tablets prepared with sodium starch glycolate have good storage properties. 
Sodium starch glycolate is stable although very hygroscopic, and should be stored 
in a well-closed container in order to protect it from wide variations of humidity 
and temperature, which may cause caking. The physical properties of sodium 
starch glycolate remain changed for up to 3 years if it is stored at moderate 
temperatures and humidity. 
9. Applications in Pharmaceutical Formulation: 
             Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. It is commonly used in tablet 
prepared by either direct compression or wet granulation processes. 
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 5.2.3   STEARIC ACID  
1.  Nonproprietary Name 
 BP         Stearic acid 
 JP          Stearic acid 
                         Ph Eur   Acidum stearicum 
                         USPNF Stearic acid  
  2. Synonym : 
  Crodacid, E570, Emersol, Kortacid 1895, Pristerene. 
3. Chemical Name and CAS Registry Number: 
         Octadecanoic acid [57-11-4] 
4. Empirical Formula and Molecular Weight: 
         C18H36O2 , 284.47 
5. Structral Formula: 
 
     
 
 
 
 
STEARIC ACID 
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6. Functional Category: 
Emulsifying agent, solubilising agent, tablet and capsule lubricant. 
 
7. Applications in Pharmaceutical Formulation or Technology 
 It is widely used in oral and topical pharmaceutical formulations. It is used in 
oral formulations as a tablet and capsule lubricant, it is also used as binder or in 
combination with shellac as a coating, and it is also used as a hardening agent in 
glycerine suppositories 
8. Uses of Stearic acid 
                           Table 5.3 Uses of Stearic acid 
                 Use       Concentration (%) 
Ointments and creams 1-20 
Tablet lubricant 1-3 
      
9. Description 
It is a hard, white or faintly yellow- coloured, somewhat glossy, crystalline 
solid or a white or yellowish white powder. It has a slight odor and taste. 
10. Typical Properties 
             Acid value        :  200-212 
            Density (bulk)    :  0.537g/cm
3
 
            Density (tapped): 0.571g/cm
3
 
           Density (true)      : 0.980g/cm
3
 
               
Melting point       :> 54ºC 
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Solubility:    Freely soluble in benzene, carbon tetrachloride, chloroform and       
ether, soluble in ethanol, hexane and propylene glycol. Practically insoluble in water. 
11. Stability and Storage Conditions 
 Stearic acid is a stable material. The bulk material should be stored in a  well 
closed container in a cool, dry place. 
12. Incompatibilities 
                   Incompatible with most metal hydroxides and oxiding agents.  
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5.2.4 STARCH 
  
1. Nonproprietary Name : 
BP            Maize starch 
               Potato starch 
              Rice starch 
              Tapioca starch 
JP       :  Corn starch 
              Wheat starch 
              Potato starch 
              Rice starch 
PhEur :  Maydis amylum (maize starch) 
              Solani amylum (potato starch) 
              Oryzae amylum (rice starch) 
              Tritici amylum 
2. Synonym : 
               Amido, amidon , amylum 
3. Chemical Name and CAS Registry Number : 
   Starch, [9005-25-8]  
\ 
 
             STARCH 
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4. Empirical Formula and Molecular Weight: 
                  C6H10O5 , 50,000-160,000 
5. Structure: 
 
 
 
 
 
                    Structure of Amylose 
 
 
 
 
 
 
       
                  Amylopectine structure 
 
6. Functional Category: 
Glidant , tablet and capsule diluents , tablet and capsule disintegrant , tablet 
binder. 
7. Applications in Pharmaceutical Formulation or Technology : 
   It is used as an excipient primarily in oral solid-dosage form as a binder,  
 diluents and disintegrant 
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8. Description: 
Starch occurs as an odourless and tasteless, fine, white coloured powder 
comprising very small spherical or ovoid granules. 
9. Typical Properties 
pH                      :  5.5-6.5 
Density (bulk)    :  0.462g/cm
3
 
Density (tapped):  0.658g/cm
3
 
Density (true)      :  1.478g/cm
3
 
10. Stability and Storage Conditions 
Dry, unheated starch is stable if protected from high humidity. Should be 
stored in an air tight container in a cool, dry place. 
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5.2.5  POVIDONE: 
1. Nonproprietary Name : 
BP      :  Povidone 
JP       :  Povidone 
PhEur :  Povidonum 
USP   :   Povidone 
2. Synonym : 
E1201, Kollidon, Plasdone, PVP,1-vinyl-2-pyrrolidinone polymer. 
3. Chemical Name and CAS Registry Number : 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
4. Empirical Formula and Molecular Formula : 
(C6H9NO)n , 2500-3000000 
 
4. Structural Formula : 
 
 
 
 
 
 
 
 
 
 
               POVIDONE 
Study and Evaluate to Propose An Alternate API  Drug & Excipient Profile 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 60 
 
6. Functional Category: 
Disintegrant, dissolution aid, suspending agent, tablet binder. 
7. Applications in Pharmaceutical Formulation or technology : 
It is used in solid-dosage forms, as a binder in wet granulation process, used as 
a solubilizer in oral and parenteral formulations. 
8. Uses of Povidone :   
          Table 5.4: Uses of povidone 
Use Concentration (%) 
Carrier for drugs 10-25 
Dispersing agent Up to 5 
Eye drops 2-10 
Suspending agent Up to 5 
Table binder, diluent or coating agent 0.5-5 
 
 
9. Description: 
It occurs as a fine, white to creamy-white coloured, odourless hygroscopic 
powder. 
10. Incompatibility 
It is compatible in solution with a wide range of inorganic salts , natural and 
synthetic resins , and other chemicals. 
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Table 6.1: List of equipments. 
NAME OF INSTUMENTS MODEL AND MANUFACTURER 
Digital Balance Mettler Toledo PR203,China 
Rapid Mix Granulator RMG5 Anchor Mark Pvt Ltd., Ahmedabad 
Fluid bed dryer Umang Pharmatech Pvt Ltd., Mumbai 
Moisture Analyzer Advance Research Pvt Ltd., Mumbai 
Tap Density Tester  Electrolab, Mumbai 
Tablet compression machine Rimek1rotary, Ahmedabad 
Vernier Calliper Mitutoyo, China 
Hardness Tester 
 
SQC & Inspection instruments, Mumbai 
Disintegration Test Apparatus USP Tab machines, Mumbai 
Stability chamber Cintex Ind. Corporation, Mumbai 
Mechanical Stirrer Neocota, Mumbai 
Auto coater Neocota, Mumbai 
Dissolution Apparatus USP XXII ElectroLab, Ahmedabad 
HPLC with Autosampler  Waters, USA 
pH meter Metro HM, Switzerland 
Differential scanning calorimeter Shimadzu  DSC 60, Japan  
UV spectrophotometer Shimadzu-1700 Pharmaspec UV-VISIBLE 
spectrophotometer, Japan 
 
FTIR spectrophotometer Brucker, Japan 
   
 6.1 LIST OF EQUIPMENTS 
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 Table 6.2: List of materials. 
S.No. Drug/ Excipients Name of supplier 
1 Naproxen sodium Granules India Ltd., Hyderabad 
2 Micro crystalline cellulose Brahmar cellulose Pvt Ltd., Cuddalore 
3 Povidone K-30 Vijilak pharma, Hyderabad 
4 Stearic acid Granules India Ltd, Hyderabad 
5   Corn starch Signet chemical corporation Pvt Ltd., 
6 Sodium Starch Glycolate SD Fine –Chem Pvt Ltd., Mumbai 
7 Aquarius BP 17066 Colorcon Asia Pvt Ltd., Mumbai 
           
                   
    6.2 MATERIALS USED 
  
 
 
 
EXPERIMENTAL 
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7.1. Performing the tests according to specification standards 
 
 7.1.1. SOLUBILITY:                                           (IP, 2007) 
                   Aqueous solubility is an important physicochemical property of the drug 
substance which determines its systemic absorption and in turns its therapeutic 
efficacy. 
                             Table 7.1: Solubility specifications 
Descriptive terms. 
Approximate volume of solvent in milli 
litres per gram of solvent. 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 1 to 30 
Sparingly soluble From 30to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 100 to 10,000 
Practically insoluble More than 10,000 
    
7.1.2. pH:                                                                (IP,2007)              
    The pH is the measure of negative logarithm of hydrogen ion concentration of 
an aqueous solution. It is one of the most important factors from which the stand point 
of solubility, stability and physiochemical suitability of a formulation. 
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Procedure: 
  1 g of Naproxen sodium is dissolved in 100ml of demineralised water for 
preparing 1% of solution. The pH value of a solution is determined potentiometrically 
by means of a glass electrode 
7.1.3. MELTING POINT:                                       (IP, 2007) 
The temperature at which the first particle of the substance completely melts 
is regarded   as melting point of the substance. The temperature at which the first 
particle starts to melt and last particle completely melts is regarded as the range of 
melting point.  
7.1.4. IDENTIFICATION TESTS:                        (USP, 2004 ) 
7.1.4.1. Identification by IR: 
 Sample Preparation: 
            Dissolve 50 mg in 5 ml of water, add 1 ml of dilute sulphuric acid, and then 
add 5 ml of ethyl acetate shake well. Allow the two layers to separate. Evaporate the 
upper layer to dryness and subsequently dry at 60ºC for 15 minutes. Transfer 1-1.5 
mg of the above prepared sample, use KBr as disc. 
Pellet preparation of test sample: 
                     Weight about 1 mg of sample and 100 mg of dried Potassium Bromide mix 
and grind in a mortar to a fine powder, spread the mixture uniformly in a die and 
submit in a vacuum to a pressure of about 800Mpa by using pellet making apparatus 
and check the pellet for uniform transparency. 
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 Pellet preparation of standard: 
           Weight about 1 g of Naproxen sodium USP working standard and 100 mg of 
dried Potassium Bromide mix and grind in a mortar to a fine powder , spread the 
mixture uniformly in a die and submit in a vacuum to a pressure of about 800Mpa by 
using pellet making apparatus and check the pellet for uniform transparency.         
Record the spectra of the test sample and the reference sample over the range from 
about 2.6µm to 15µm (13800 cm
-1 
). Overlap the sample spectrum with reference 
spectra and observe the overlap spectrum of test and reference. The IR spectrum of 
the sample must be concordant with that of the reference spectrum. 
7.4.1.2. UV:  
    Test solution: 
          Weigh about 50 mg of Naproxen powder; note it down, transfer into 100 ml 
volumetric flask, dissolve in methanol and make up to volume with the same 
solvent. Pipette out 5 ml of the above solution accurately into 100 ml volumetric 
flask and make up to volume with methanol. 
 Reference solution: 
         Weigh 50 mg of Naproxen working standard, note it down, transfer into 100 
ml volumetric flask, dissolve in methanol and make upto volume with the same 
solvent. Pipette out 5 ml of the above solution accurately into 100 ml volumetric 
flask and make up to volume with methanol. 
             Record the spectrum for both the test solution and reference solution over the 
spectral range from 200-400 nm in 1 cm cell. 
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          Calculate the absorptive at 272 nm for test solution and reference solution on 
dried basis. The difference is not more than 3 %. 
   Calculation: 
   Λ max 272 nm 
      𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  𝑎1 =
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒  𝑜𝑓  𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  ×100×100×100×100
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  𝑤𝑒𝑖𝑔 𝑕𝑡×5×𝑝𝑢𝑟𝑖𝑡𝑦 ×(100−𝐿𝑂𝐷)
 
 
𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑣ity of s𝑎𝑚𝑝𝑙𝑒 𝑎2 
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 × 100 × 100 × 100
 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 × 5 × 𝑝𝑢𝑟𝑖𝑡𝑦 × (100 − 𝐿𝑂𝐷)
 
 
%𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑜 𝑡𝑕𝑎𝑡 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 =
(𝑎1−𝑎2)×100
𝑎1
  
The respective absorptivities at 272 nm, do not differ by more than 3% 
 
7.1.1.3. Sodium reaction: 
    Dissolve 0.1 g of sample in 2 ml of water; add 2 ml of a 150 g/ml solution of 
potassium carbonate and heat to boiling, no precipitate is formed. Add 4 ml of 
potassium pyroantimonate solution and heat to boiling allow cooling with ice water 
and if necessary rubbing the inside of the test tube with a glass rod –a dense white 
precipitate is formed. 
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7.1.5. Specific optical rotation: 
   Sample preparation:  
       Accurately weight and transfer about 2.5 g of Naproxen sodium into a clean 
and dried 50 ml volumetric flask, add 15 ml of 0.1 N sodium hydroxide, shake well to 
dissolve the sample and make up to the mark with 0.1 N sodium hydroxide solution . 
    Instrument parameters: 
    sample temperature      :25°C 
    cell length                     :1dm 
   𝑺𝒂𝒎𝒑𝒍𝒆 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 =
𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒂𝒎𝒑𝒍𝒆×(𝟏𝟎𝟎−𝑳𝑶𝑫)
𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝟎.𝟏𝑵 𝑵𝒂𝑶𝑯 𝒕𝒂𝒌𝒆𝒏
 
          Procedure: 
  Take a clean and dried 1 dm glass cell or quartz cell. Perform blank 
determination by using 0.1 N sodium hydroxide as blank in a polarimeter. Then take 
the sample into cell and perform the specific optical rotation for sample and take five  
                                          𝛼 = 𝜆
100×𝑎
𝑙𝑐
                                 
          α = Optical rotation at wave length 589 nm 
          t =Temperature 
          λ =Wavelength (589 nm) 
          a =observed rotation in degrees 
          l =Path length in decimeters 
          c =concentration of solution 
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7.1.6. Heavy metals:                                                    (USP, 2004) 
  Reagents: 
 6N HCl: Dilute 51.0 ml of HCl with water to 100 ml. 
 6N Ammonium Hydroxide: Dilute 400 ml of Ammonia water, stronger with 
water to make 1000 ml. 
 1 N Acetic acid: Add 58 ml of glacial acetic acid to sufficient water to make 
1000 ml after cooling to room temperature. 
 1 N NaOH: Dissolve 40 g of sodium hydroxide in carbon dioxide free water, 
cool the solution to room temperature, and filter thorough hardened filter 
paper. 
 Thioacetamide Glycerin Base TS: 
 Mix 0.2 ml of thioacetamide and 1 ml of glycerine base TS. Heat it on a 
water bath for 20 sec. Use the mixture immediately. 
 Lead Nitrate Stock Solution: 
    Dissolve 159.8 mg of lead nitrate in 100 ml of water to which has been added 
1 ml of nitric acid, then dilute with water to 1000ml. Prepare and store this solution in 
glass container free from soluble lead salts. 
 Standard Lead Solution : 
       Each ml of the standard lead nitrate stock solution with water to 100 ml, a 
comparison solution prepared in the basis of 100 ml of standard lead solution 1 g of 
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substance being tested contains the equivalent of 1 part of lead per million parts of the 
substance being examined. 
  Standard Preparation: 
              Pipette out 2 ml of standard lead solution (20µg of Pb) into a 50 ml colour 
comparison tube and dilute with water to 25 ml, adjust with 1 N acetic acid or 6 N 
ammonium hydroxide to a pH between 3.0 and 4.0 using short range pH indicator 
paper as external indicator. Dilute it with water to 40 ml and mix. 
Test Preparation:  
 Weigh accurately 1.0 g of test sample and transfer into a separator. Add 20 ml 
of water and shake to dissolve the sample, add 5 ml of 1 N HCl and extract with 
successive 20, 20 and10 ml portions of methylene chloride. Discard the Methylene 
chloride extracts, take aqeous layer, make up to 25 ml with water and transfer into 50 
ml colour comparison tube. Adjust the above solution with 1 N Acetic acid or 6 N 
Ammonium hydroxide to a pH between 3.0 and 4.0 using short range pH indicator 
paper as external indicator. Dilute it with water to 40 ml and mix. 
   Standard Preparation: 
  To the test preparation add 2.0 ml of lead acetate solution and adjust the above 
solution with 1N Acetic acid or 6N Ammonium hydroxide to a pH between 2.0 and 
4.0 using short range pH indicator paper as external indicator. Dilute it with water to 
40 ml and mix.  
   Test procedure: 
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             Add 2.0 ml of 3.5 pH buffer solution and then 1.2 ml of thioacetamide glycine 
base TS to each of the tube containing the standard preparation, the test preparation 
and standard preparation. Dilute with water to 50 ml, mix and allow it to stand for 2 
minutes. 
7.1.7. Loss on Drying:                                       (Lachman L.,et al.,1991)
 
Weigh accurately previously dried and cooled crucible and record weigh as   
W1. 
            Transfer about 1.0 ± 0.1 g of sample into crucible, weigh accurately and 
record the weight of the sample and crucible as W2. 
                   Weigh of sample taken =W2-W 1 
                 Dry the sample in an oven at 105º C for 3 hrs. After completion of drying, cool 
the sample to room temperature in a desicator and record total weight as W3. 
                         Loss in weight after drying= w2-w3 
      Calculation: 
                      %𝐿𝑜𝑠𝑠 𝑂𝑛 𝐷𝑟𝑦𝑖𝑛𝑔 =
𝑊2−𝑊3
𝑊2−𝑊1
× 100 
7.1.8. Determination of percentage purity of drug:                            (IP, 2010) 
            Although the specifications for assay results differ from product to product, 
generally the expected range for individual active ingredient is to be within 90%–
110% of the labelled amount.  
 Instrument: 
             HPLC equipped with UV detector and data handling system. 
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Apparatus: 
            Analytical balance, volumetric flasks, Pipettes, 0.45µ membrane filters. 
 Chemicals and reagents: 
 Triethylamine -GR grade 
 Glacial acetic acid-HPLC grade 
 Purified water -Milli-Q grade 
 Acetonitrile -HPLC grade 
 Naproxen sodium working standard 
 Chromatographic conditions: 
 Column:                    A Stainless steel column packed with octadecyl 
silane bonded to porous silica (5µm) 
 Flowrate:                    1.5ml/min 
 Wavelength:               260 nm 
 Column temperature:  30˚C 
 Injection volume:        20µl 
 Run time:                   12 min. 
 
 Preparations: 
1. Buffer preparation: Accurately weigh and transfer about 5.0 ml of 
Triethylamine into 1000 ml of purified water. Adjust the pH of solution to 
5.0 with 50 % glacial acetic acid. Filter the solution through 0.45µm 
Millex-HV PVDF filter and degassed. 
2. Mobile phase –A preparation:  Prepare a filtered and degassed mixture 
of buffer solution and Acetonitrile in ratio of 60:40 v/v respectively. 
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3. Mobile phase –B preparation: Prepare a filtered and degassed mixture of 
buffer solution and Acetonitrile in ratio of 10:90 v/v.  
4. Diluent preparation: Mix Milli Q water and Acetonitrile in ratio of 90:10 
v/v respectively.    
 
5. Naproxen sodium Reference preparation: 
                           A 0.1% W/V solution of Naproxen sodium RS in the mobile phase 
dilute 5.0 ml of the solution to 50.0 ml with the mobile phase. 
6. Sample preparation: 
   Dissolve 50 mg of the substance under examination in 50.0 ml of the mobile phase 
dilute 5.0 ml of the solution to 50.0 ml of the mobile phase  
 Procedure: 
  Seperately inject equal volumes (about 20µl) of the water as blank, standard 
preparation and sample preparation into chromatograph and record the 
chromatograms and measure the peak area response for analyte peak. Calculate the 
percentage content of Naproxen sodium taken by formula. 
 Percentage content of Naproxen sodium 
 TA / SA *   SW / 250 *   2/20   *   250/TW   * 100/1 * P/100 *    100                  
Where, 
TA = Peak area response due to Naproxen sodium from sample preparation 
SA= Peak area response due to Naproxen sodium from   standard preparation 
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SW=Weight of Naproxen sodium working standard taken in mg. 
TW=Weight of sample taken in mg. 
P   =Purity of Naproxen sodium working standard taken on, as is basis 
 
7.1.9. Related Substances by HPLC:                              (USP, 2004) 
       Impurities  
      Impurity-A:  2-(3-hydroxy-2.2-dimethylpropoxy)-1-(6-hydroxy-2-napthyl)propan-   
                          1-one 
      Impurity-B: 1-(6-methoxynapthalen-2-yl) ethanone 
      Impurity-C: (1RS)-1-(6-methoxynapthalen-2-yl) ethanol 
      Impurity-D: 2-bromo-6-methoxynapthelene. 
   Chromatographic System: 
               Column                       :    C18  
               Wavelength                :    230 nm 
               Flow rate                    :   1.5 ml/min 
              Column temperature   :    50°C 
             Injection volume         :    20µl 
             Run time                     :    1.5 times the retention time of impurity B. 
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Mobile Phase Preparation: 
      Mix 42 volumes of acetonitrile and 58 volumes of a 1.3g/l solution of 
potassium dihydrogen   phosphate previously adjusted to pH 2.0 with phosphoric acid. 
 
Solution Preparation  
Test solution    
Dissolve 30 mg of sample in the mobile phase and dilute to 50 ml with the 
mobile phase. 
Reference solution (a): Dilute 1.0 ml of the test solution to 50 ml with the mobile 
phase, shaking then dilute 5 ml of this solution to 100 ml with mobile phase. 
Sensitivity solution    : Dilute 2ml of reference solution (a) to 10 ml with the mobile 
phase. 
Reference solution (b): Dissolve each 6 mg of all the impurities in acetonitrile and 
dilute to 10 ml with the same solvent, get the impurities stock solution. To 1mL of the 
solution add 1 ml of the test solution and dilute to 50 ml with the mobile phase. Dilute 
5 ml of this solution to 100 ml with the mobile phase get the reference solution-b. 
Test Procedure  
 A) Inject 1 replicate of blank solution 
B) Inject 1 replicate of sensitivity solution, and require S/N of main peak not less than 
10. 
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C) Inject 3 replicates of reference solution (b), the resolution between the peak due to    
impurity C and Naproxen should not be less than 2.2. The tailing factor of impurity –
A and impurity B should be between 0.8~ 1.5. 
D) Inject 3 replicates of reference solution (a), record the main peak area calculate the 
mean peak areas and require the RSD not more than 5.0%. The tailing factor of main 
peak should be between 0.8~ 1.5. 
E) Inject 1 replicate of test solution record each impurity peak areas, calculate the 
specified impurity-A and impurity-B by external standard method. 
Specified Impurity: 
                                     𝑰𝒎𝒑𝒖𝒓𝒊𝒕𝒚 − 𝑨 𝒐𝒓 𝑩% =
𝑨𝑺
𝑨𝑹
×
𝑴𝑹
𝑴𝑺
×
𝟏
𝟐𝟎𝟎
 
Where 
  AS A R = the peak areas of impurity-A or B obtained with test solution and reference 
solution (b) separately. 
MS, MR = the weight of impurity-A or B reference standard and sample separately. 
𝑨𝒏𝒚 𝒐𝒕𝒉𝒆𝒓 𝒊𝒎𝒑𝒖𝒓𝒊𝒕𝒚 % =
𝑨𝑺
𝑨𝑹
×
𝑴𝑹
𝑴𝑺
× 𝟎. 𝟏% 
Where 
AS      = peak area of any other impurity (maximum) expect impurity-A or B obtained 
with test solution. 
AR   = mean area of main peak obtained with reference solution (a) 
MS   = sample weight in mg 
MR   = sample weight corresponding to reference solution (a) in mg  
         Total impurities: 
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𝐼𝑚𝑝𝑢𝑟𝑖𝑡𝑦 − 𝐴% + 𝑖𝑚𝑝𝑢𝑟𝑖𝑡𝑦 − 𝐵% + 𝐴𝑛𝑦 𝑜𝑡𝑕𝑒𝑟 𝑖𝑚𝑝𝑢𝑟𝑖𝑡𝑦 +
𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 𝑜𝑡𝑕𝑒𝑟 𝑖𝑚𝑝𝑢𝑟𝑖𝑡𝑖𝑒𝑠%. 
 
7.2. Formulation of Naproxen sodium tablets. 
7.2.1. Dry mixing: 
    Naproxen sodium,  
Microcrystalline cellulose, Corn starch and Sodium starch glycolate were loaded into 
the rapid mixer granulator and mixed for 10 minutes at slow mixer speed. 
7.2.2. Preparation of binder: 
    Povidone K-30 is dissolved in purified water by stirring. 
7.2.3. Wet granulation: 
   The binder solution was added to the above powder with the mixer at fast speed and 
the chopper at fast speed. 
 Wet mixing should be continued until the required end point was achieved. 
 The material was then unloaded into Fluidised Bed Dryer (FBD) bowl. 
7.2.4. Drying: 
   The wet granules were dried until required LOD was achieved. 
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7.2.4. Sifting and milling: 
   The dried granules were then sifted through double deck vibro sifter using #16/150 
or SD sifter with #16 mesh screen; knives were forward at medium speed and then 
resifted. 
7.2.5. Blending before addition of lubricants: 
   Granules were then loaded into the blender for the specified time. 
7.2.6. Blending after addition of lubricants: 
   Lubricants were then sifted through #40 mesh screen and then were added into the 
blender and were blended for the specified time. 
A sample was analysed for physical parameters and a sample of granules were 
compressed into table. 
Table 7.2: Process parameters used in formulation of Naproxen 
sodium. 
S.No Parameters Results 
1 Purified water used 0.930 l 
2 Inlet temperature 76°C 
3 Bed temperature 58°C 
4 Atomizing air pressure 3.9m/sec 
5 Fluidizing air volume 65m/sec 
6 % LOD w/w at 105°C 0.67% 
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7.2.7. Coating: 
   The coating suspension was made with Aquarius BP 17066 in purified 
water. The suspension was used to coat the tablets in the coating pan. 
Table 7.3: Coating parameters. 
S.No Parameters Quantity 
1 Aquarius BP 17066 21.0 mg 
2 Purified water 119.0 ml 
3 Core tablets 700 
 
Table 7.4: Composition of Naproxen sodium tablets using both the API’S       
S.No Name of the Ingredient REDDY’S(mg) CHARIOTEER(mg) 
1 Naproxen sodium  USP 220 220 
2 Microcrystalline cellulose  38.599 41.57 
3 Corn starch  26.999 23.999 
4 Sodium starch glycolate  2.999 5.999 
5 Povidone K30 8.999 5.999 
6 Water qs qs 
7 Stearic  acid  2.3999 2.3999 
8 Total weight 300 300 
*All the quantities are expressed as mg per tablet. 
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7.3 Evaluation of pre compression parameters for both the API’S  
7.3.1. Angle of repose:                                                (USP29-NF-24) 
This is the maximum angle possible between the surface pile of powder and 
horizontal plane. The frictional forces in the lose powder can be measured by angle of 
repose. The tangent of angle of repose is equal to the co-efficient friction (µ) between 
the particles. Hence the rougher & more irregular the surface of particles the greater 
will be angle of repose. The interrelationship between the angle of repose and flow 
properties of powder are shown in the Table 3.5. Angle of repose is calculated by the 
following formula. 
                                                      θ  =tan-1(h/r) 
 Where,  θ = angle of repose, r=radius of the pile, h=height of the pile,  
     Table 7.5: Standard values of angle of repose (º). 
S.No Flowability Angle of repose 
1 Excellent ˂25 
2 Good 25-30 
3 Passable 30-40 
4 Poor 37-45 
5 Very poor >45 
                         * Adding glidant for improving flow 
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7.3.2. Carr’s Index:                            
Carr‟s Index is measured using the values of the bulk density and tapped 
density. 
The following equation is used to find the Carr‟s index  
                            𝐶𝑎𝑟𝑟 ′𝑠𝐼𝑛𝑑𝑒𝑥 =
𝑇𝑎𝑝𝑝𝑒𝑑  𝑑𝑒𝑛𝑠𝑖𝑡𝑦 ×𝐵𝑢𝑙𝑘  𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑇𝑎𝑝𝑝𝑒𝑑  𝑑𝑒𝑛𝑠𝑖𝑡𝑦
100 
Compressibility Index and Hausner ratio :-   (Lachman L.et al.1991) 
In recent years the compressibility index and the closely related Hausner ratio 
have become the simple, fast, and popular methods of predicting powder flow 
characteristics. Both the compressibility index and the Hausner‟s ratio were 
determined by using bulk density and the tapped density of a powder.  
𝑪𝒐𝒎𝒑𝒓𝒆𝒔𝒔𝒊𝒃𝒊𝒍𝒊𝒕𝒚 𝒊𝒏𝒅𝒆𝒙 =
𝑻𝒂𝒑𝒑𝒆𝒅 𝒅𝒆𝒏𝒔𝒊𝒕𝒚 − 𝒃𝒖𝒍𝒌 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
𝑻𝒂𝒑𝒑𝒆𝒅 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
× 𝟏𝟎𝟎 
             𝑯𝒂𝒖𝒔𝒏𝒆𝒓′𝒔 𝒓𝒂𝒕𝒊𝒐 =
𝑻𝒂𝒑𝒑𝒆𝒅 𝒃𝒖𝒍𝒌 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
𝒍𝒐𝒐𝒔𝒆 𝒃𝒖𝒍𝒌 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
 
Relation of flow property with Hausner‟s ratio and Compressibility index is shown in 
table 
                        Table 7.6: Standard values of Carr’s index. 
Compressibility 
Index (%) 
Flo Characteristics  Hausner’s Ratio 
5-10 Excellent 1.00–1.11 
12–16 Good 1.12–1.18 
18–21 Fair-passable 1.19–1.25 
23–35 Poor 1.26–1.34 
33–38 Very poor 1.35–1.45 
                                 *May be improved by glidant. 
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7.4 Evaluation of post compression parameters of both the API’S 
Formulations 
7.4.1 Organoleptic properties:   (Lachman L.,et al.1991, Bankar G.S. and Rhod C.T. 
1996) 
Many pharmaceutical tablets use colour as a vital of rapid identification and 
consumer acceptance. The colour of a product must be uniform within a single tablet 
is generally   referred to as “mottling”, from tablet to tablet, and form lot to lot non 
uniformity of colouring not only lacks aesthetic appeal but also could be associated by 
the consumer with non-uniformity of content and general poor quality of the product. 
7.4.2Weight variation test                  (IP, 2007, Lachman L., et al.1991) 
Weight variation test was done by weighing 20 tablets individually, by using 
analytical balance. Calculating the average weight and comparing the individual tablet 
weight to the average weight. 
7.4.3. Tablet thickness
                                   
(Lachman L., et al.1991) 
Thickness was determined  for 5 preweighed tablets of each batch using a 
digital vernier scale and the average thickness was determined in mm. the tablet 
thickness should be controlled within a +5 % variation of a standard. 
7.4.4. Tablet hardness
                                      
(Lachman L., et al.1991, Bankar G.S. and 
Rhodes C.T.   1996)
   
The tablet hardness, which is the force required to break a tablet in a diametric 
compression force. The hardness tester used in the study was Monsanto hardness 
tester, which applies force to the tablet diametrically with the help of an inbuilt spring. 
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7.4.5. Friability:                   (Lachman L, et al.,1991; Bankar G.S. and Rhodes 
C.T.,1996) 
Friability is an important factor in tablet formulation to ensure that the tablet 
can stay intact and withhold its form from any outside force of pressure: 
 
Where Wo is the original weight of the tablets, and Wf  is the final weight of the 
tablets after the collection is put through the friabilator. Friability below 0.8% is 
usually considered satisfactory. 
7.46. In- vitro disintegration test           
The test was carried out on 6 tablets using Tablet disintegration tester.  Distilled water 
at 37ºC ± 2ºC was used as a disintegration media and the time in seconds taken for 
complete disintegration of the tablet with no palable mass remaining in the apparatus 
was measured.  
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Table 7.7 : Specifications of Disintegration time. 
 
  
           Tablet Type                    Time limit and Specifications 
1. BP 
 Uncoated   <15min 
 Coated 
 Film   <30min 
 Sugar              <60min, repeat in 0.1MHCl 
 Gastro resistant, enteric          >120min in 0.1MHCl 
               <60min in pH 6.8(Phosphate) 
 Effervescent              <5min in 200ml, water, 20°C 
 Soluble   <3min 
 Dispersible                     <3min, 2 tablets in 100ml water dispersed, passed 
2.USP 
 Uncoated               <15min  
 Plain coated              <30 min  
 Enteric coated Intact for 60min in simulated gastric fluid, disintegrated in simulated 
intestinal fluid<monograph time 
 Buccal              <4hour 
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7.4.7. In-vitro dissolution:                                                (IP,2010)   
Dissolution means the process by which solid substance enters in the solvent 
to yield solution. It is controlled by the affinity between the solid substance and the 
solvent is a process in which a solid substance solubilises in a given solvent that is 
transfer from the solid surface to the liquid phase. 
Medium              :   pH 7.4 phosphate buffer 
Volume               :   900 ml 
Apparatus          :   USP-II, paddle 
Speed                  :   50 rpm  
Temperature      :  37+ 0.5°C 
Sampling points  :  60 mins.  
7.5. STABILITY STUDY                        (Manavalan R. and Ramasamy S. 2004) 
 Introduction 
In any rational drug design or evaluation of dosage forms for drugs, the 
stability of the active component must be a major criterion in determining their 
acceptance or rejection. Stability of a drug can be defined as the time from the date of 
manufacture and the packaging of the formulation, until its chemical or biological 
activity is not less than a predetermined level of labelled potency and its physical 
characteristics have not changed appreciably or deleteriously. 
 Objective of the study 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
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recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled “Stability testing of New Drug Substances and Products (QIA) 
describes the stability test requirements for drug registration application in the 
European Union, Japan and the States of America. 
ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25
0 
C ±2
0 
C at 60% RH ±5% for 12 Months  
 Accelerated Testing: 40
0 
C ±2
0 
C at 75% RH ±5% for 6 Months  
In present study both the formulations of two different API‟S were exposed up 
to 3 months stability studies at accelerated condition (40
0 
C ±2
0 
C at 75% RH 
±5%RH) to find out the effect of aging on hardness, disintegration, drug content and 
In-Vitro drug release.  
 Procedure 
Stability studies were carried out at accelerated condition (40
0 
C ±2
0 
C at 75% 
RH ±5%RH) for both the formulations. The tablets were stored at 40
0 
C ±2
0 
C at 75% 
RH ±5%RH for accelerated temperature in closed high density polyethylene bottles 
for 3 months. The samples were withdrawn after periods of 1 month, 2 month and 3 
month. The samples were analyzed for its hardness, floating, disintegration, drug 
content and In-Vitro drug release.  
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7.5.1 Stability Studies:                                                        (Bentley’s.2003) 
 Both the formulations were subjected to stability studies as per ICH 
guidelines at 30°C/ 65 % RH and 40°C / 75% RH for 3 month. Samples were taken 
and analyzed at time interval. Selected formulations were subjected to stability studies 
as per ICH guidelines sample were taken and analyzed at time interval of 15 days for 
3 months.  
Table 7.8:  Stability Studies. 
S.No STUDY STORAGE CONDITION 
TIME 
PERIOD 
1. Long term 
25ºC+ 2ºC/60 %RH+ 5ºC (or) 30C+2ºC/ 
65%RH+5%RH 
12 months 
2. Intermediate 30ºC+2ºC/65%RH+5%RH 6months 
3. Accelerated 40ºC +2ºC / 75% RH +5 % RH 6months 
   
  
 
 
 
 
 
 
RESULTS  
AND  
DISCUSSION 
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8.1. Results and Discussion for Approved vendor 
8.1.1. Certificate of Analysis for the API of approved vendor: 
Table 8.1: Certificate of Analysis for approved API. 
S.No Test Result 
1 Appearance White crystalline powder. 
2 Solubility Freely soluble in water, and in 
methanol, sparingly in alcohol, 
insoluble in chloroform and 
toluene 
.3 Specific optical rotation -16.76 
4 Assay (w/w) 99.8 %w/w 
5 Heavy metals(%w/w) Less than 0.002% 
6 Loss on drying Not more than 1% 
7 Related substances impurities Not more than 0.1 % 
8 Particle size 
a)Small or equal to 300µm 
b)Small or equal to212 µm 
 
Not less than 90% 
Not less than 50% 
9 Bulk density(g/ml) 
a)untapped 
b)tapped 
 
0.632 
0.793 
 
 
 
8. RESULTS AND DISCUSSION 
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8.2. Performing the tests according to specification standards 
      8.2.1. Solubility study 
Table 8.2: Solubility of Naproxen sodium for approved API formulation 
 
 
 
 
 
 
 
 
   8.2.2. Melting point: 
 Melting point values of Naproxen sodium sample was found to be in range of 
152
0
C to 157
0
C. The reported melting point for Naproxen sodium was 154
0
C. 
8.2.3Identification Tests: 
              8.2.3.1   Identification by FT-IR spectroscopy 
The FT-IR spectrum of Naproxen sodium for the API of REDDY‟S was 
shown in figure 8.1 and the interpretations of IR frequencies were showed in table 
8.3. 
 
 
 
 
Name of solvent Solubility 
Distilled water Soluble 
Methanol Soluble 
Alcohol Sparingly soluble 
Acetone Very slightly soluble 
Chloroform Insoluble 
Toluene Insoluble 
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Figure 8.1: FT-IR spectrum of Naproxen sodium for approved API formulation 
 
Table 8.3: Characteristic IR Peaks of Naproxen sodium for approved API 
formulation 
         Wave Number in cm 
-1
                  Characteristics 
  3056.12 – 2955.82   Aromatic C-H stretching 
  2745.31 – 2364.13   Overtone 
  1630.47   C=O stretching 
  1579.78   Presence of C-O stretching 
  1478.06 -1360.78   CH3, CH2 bending 
  1207.04   C-O bending 
  956.52 – 620.00   CH2 bending 
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8.2.3.2. UV Method: 
    The absorption maximum for Naproxen sodium was found to be at 
272.16 nm. 
 
 
 
 
                                       
 
 
 
.                  Figure 8.2:  λ max of Naproxen sodium for approved API formulation 
8.2.4. Specific optical rotation: 
 The reported specific optical rotation for Naproxen sodium was found to be at 
about -16.76.Hence the value complies with that of the standard USP values.  
Table 8.4: Specific optical rotation for approved API formulation 
 
 
 
 
 
 
 
S. No. Specific optical rotation Average Specific optical 
rotation 
1 -16.76  
-16.76±0.55 2 -15.8 
3 -16.76 
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8.2.5. Heavy metals: 
  The reported amount of heavy metals for Naproxen sodium was found 
to be 0.001±0.00032 % w/w. Hence the value complies with that of the standard USP.  
                Table 8.5: Test for heavy metals for approved API formulation 
       
8.2.6. Loss on Drying :    
The percentage loss on drying after 3 hours was found to be as follows: 
Table 8.6: Percentage loss on drying for approved      
 API formulation 
Sample passes test for loss on drying as per the limit specified in IP and USP 
(N.M.T 1%) 
 
 
 
 
 
S. No Heavy metals (%w/w) Avg. percentage of Heavy 
metals. 
1 0.001  
0.001±0.00032 
 
2 0.0016 
3 0.0015 
S. No. Percentage  LOD Average percentage LOD 
1 0.5  
0.3±0.115 
 
2 0.3 
3 0.3 
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8.2.7. Related substances Impurities: 
 
 
 
 
 
 
 
 
 
 
Figure 8.3: Related substances impurities Blank. 
 
 
 
 
 
 
 
 
 
 
 Figure 8.4: Impurities present in Naproxen sodium. 
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Table 8.7: Impurities present in Naproxen sodium for approved API formulation 
  S. No Peak Name      RT Area % Area 
 1 Naproxen 
sodium 
2.378 2744 0.01 
3.470 18300022 99.92 
 2  4.513 654 0.00 
 3 Impurity-D 4.883 328 0.00 
 4 Impurity-A 7.023 8528 0.05 
 5 Impurity-B 9.050 - - 
 6  9.431 1834 0.01 
 7 Impurity-C 11.760 - - 
The related substances impurities for Naproxen sodium was found to be within the 
limits as per USP standards (NMT 0.1) 
8.2.8. Determination of percentage purity and linearity of the drug: 
8.2.8.1. Preparation of standard graph of Naproxen sodium: 
 The drug obeys Beer- Lambert‟s law in the range of 10–50μg /ml. 
           Table 8.8:  Standard graph of Naproxen sodium in pH 7.4 phosphate    
          buffer for approved API formulation 
S. No. Concentration 
(µg/ml) 
Area of the peak 
1 10 1281809 
2 20 2563618 
3 30 3845467 
4 40 5127276 
5 50 6409124 
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Figure 8.5:  Standard graph of Naproxen sodium for approved API formulation 
 Table 8.9:  Standard graph parameters for Naproxen sodium in pH 7.4                   
phosphate buffer for approved API formulation 
 
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope  128180.9 
3 Intercept 2219800 
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8.2.8.2. Percentage purity of drug 
The percentage purity of drug was calculated by using HPLC Chromatographic 
method. The reported percentage purity was found to be 99.8±0.12%w/w. 
Table 8.10: Percentage purity of Naproxen sodium for approved API 
formulation 
 
  
 
 
 
 
  
                     The reported % purity for Naproxen sodium in IP is 97-102%   w/w. 
8.3. Differential scanning calorimetry: 
 DSC was performed for pure drug Naproxen sodium for approved vendor. 
 
Figure 8.6:DSC thermogram of Naproxen for approved API formulation 
S. No. Percentage purity (%) Avg. percentage 
purity (%) 
1 99.8 
 
99.8±0.12 
2 99.7 
3 99.8 
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8.3 Evaluation of Precompression parameters for approved API 
 The blended powders of the formulation   were evaluated for angle of 
repose, loose bulk density, tapped bulk density, compressibility index and Hausner„s 
ratio. The results of these evaluations were as follows: - 
           Table.8.11: Granulation tests for approved API formulation 
 
S.NO  TEST  RESULT 
1  Sieve analysis   
   ASTM mesh no   
 20  26.5  
 40  61.5  
 60  75.0  
 80  83.0  
 100  86.5  
 200  95.5  
2  Moisture content  1.95%  
3  Angle of repose*  27.4°  
4  Bulk density: *  
    Untapped  0.632±0.00 g/ml  
    Tapped  0.793±0.00 g/ml  
5 Compressibility index* 14.86 ±0.03% 
6 Hausner‟s ratio* 1.16±0.00 
 *All the values were expressed as mean ± SD, n=3* 
8.3.1. Angle of repose: 
            The reported angle of repose was found to be 27.4°, hence the blend was 
found to have good flowability.  
  
8.3.2. Loose bulk density and tapped bulk density: 
            Bulk and tapped densities were used for the measurement of Compressibility 
index. The loose bulk density was found to be 0.632±0.00g/ml and tapped bulk 
density was found to be 0.793±0.00g/ml. 
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8.3.3 Compressibility index (Carr’s index): 
 The compressibility index was found to be 14.86±0.00%. The blend was found 
to have good   flowing property as the result were found to be below 16%.  
 8.3.4. Hausner’s ratio: 
The Hausner‟s ratio was found to be 1.16±0.00. The result indicates the free flowing 
properties of the powders. 
8.4 Evaluation of Post compression parameters for approved API 
8.4.1. Appearance: 
 Surface nature of tablets was observed visually and it was concluded   that 
they did not show any defects such as capping, chipping and lamination. 
8.4.2. Organoleptic properties 
Odour:  Odourless  
Colour:  White or almost white  
Nature: Crystalline powder.  
8.4.3. Physico-chemical characteristics:  
The physical characteristics of Naproxen sodium tablets such as thickness, 
diameter, hardness, friability, weight variation and drug content were determined and 
the results were shown in table 8.12. 
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Table 8.12: Post compression parameters for approved API formulation 
          
S. No 
 
Parameters 
 
Results 
1   Disintegration time *    9 minutes 45 sec  
2  Hardness (kg/cm2) **    9.6±0.79 
3 Diameter (mm)*   11.17±0.01 
4  Thickness (mm)*   4.76±0.07  
5  Weight variation (%) ***   301±1.50  
6 Friablity(%)**   0.31±0.015 
    *All values were expressed as mean ± SD., n=3*, n=6**, n=20*** 
 
8.4.4. Dimension (Thickness and Diameter): 
 The diameter of the tablets was found to be 11.17±0.01 mm, and thickness 
was found to be 4.76± 0.07 mm. 
 
8.4.5. Tablet hardness:  
 The hardness of tablets was found to be 9.6± 0.79 kg/cm
2
. This indicates good 
mechanical strength of tablet. 
 
8.4.6. Percentage friability: 
Percentage friability of all the formulations was found to be 0.31±0.015%. 
This indicates good handling property of the prepared matrix tablet 
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8.4.7. Weight variation: 
A tablet is designed to contain a specific amount of drug. When the average 
weight of the tablet is 300 mg, the pharmacopoeial limit for percentage deviation is ± 
5%. The weight variation was found to be 301±1.50%. The percentage deviation from 
average tablet weight for the tablets was found to be within the specified limits and 
hence the formulation complies with the test for weight variation according to the 
pharmacopoeial specifications IP. 
 
8.4.8 Drug content: 
 The drug content for the formulation was found to be 99.8±0.12%w/w, which 
was within the specified limit as per IP .The values are shown in Table 8.10 
 8.4.9. In vitro dissolution studies: 
Table 8.13: Dissolution profile of the formulation. 
  S. No Time in 
minutes* 
Percentage drug    
released 
     1          5        28 
     2         10        49  
     3         15        75  
     4         30        88  
     5         45        92  
    6         60       97.2 
                            *All values were expressed as mean ±SD, n=3*.   
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                         Figure 8.7: In-vitro drug released profile of formulation  
 
Table 8.14: Time of in-vitro drug released of t25, t 50 t90 values for approved API 
formulation 
 
S.No Time in 
min 
 t25  t 50  t90 
1 5 4.0322 8.0645 14.51 
2 10 4.237 8.4745 15.254 
3 15 4.687 9.375 16.87 
4 30 7.731 15.463 27.83 
5 45 11.25 22.5 40.5 
6 60 14.70 29.411 52.94 
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8.5 Stability studies for approved API 
After exposure to accelerated stability conditions the formulation was 
analyzed for various parameters. The results are shown in Table8.15 and Figures 8.8, 
8.9, 8.10 and 8.11 
Table 8.15: Stability studies for approved API formulation. 
S.No Parameters Initial 1
st
 month 2
nd
 month 3
rd
 month 
1 Description White 
coloured 
round shaped 
coated 
tablets 
White 
coloured 
round shaped 
coated 
tablets 
White 
coloured 
round shaped 
coated 
tablets 
White 
coloured 
round shaped 
coated 
tablets 
2 Disintegration*  
(min) 
9min45 sec    9min 42 
sec 
9min 35 sec 9min 30sec 
3 Hardness* 
(kg/cm
2
) 
   9.6±0.079    9.3±0.05   9.1±0.05   8.6±0.05 
4 Assay* 
(%w/w) 
 99.80±0.02  99.75±0.08 99.68±0.05 99.65±0.02 
5 Dissolution* 
(%) 
97.2±0.02   97.4±0.02   96.9±0.02   96.5±0.03 
                          *All the values were expressed as mean± S.D, n=3. 
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Figure 8.8: Comparison for hardness of before and after stability studies.              
 
.
 
     Figure 8.9: Comparison for disintegration time of before and after stability 
studies.              
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  Figure 8.10: Comparison for assay of before and after stability studies.                
 
Figure 8.11: Comparison for dissolution profile of before and after 
stability studies.                
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From the above studies there was no significance difference between the 
evaluated data from initial and after stability studies and all the values were found in 
worth accepting limits. The formulation showed adequate physical stability at 
40
o
C±2
o
C at 75±5% relative humidity. 
8.6. Results and Discussion for Alternate vendor CHARIOTEER’S 
8.6.1. Certificate of Analysis for the API of alternate vendor: 
Table 8.16: Certificate Of Analysis for Alternate API. 
S. No Test Result 
1 Appearance White crystalline powder. 
2 Solubility Freely soluble in water, 
and in methanol, sparingly 
in alcohol, insoluble in 
chloroform and toluene 
3 Specific optical rotation -15.6 
4 Assay (w/w) 99.7 %w/w 
5 Heavy metals Less than 0.002% 
5 Loss on drying Not more than 1% 
6 Related substances impurities Not more than 0.1 % 
7 Particle size 
a)Small or equal to 300µm 
b)Small or equal to212 µm 
 
Not less than 90% 
Not less than 50 % 
8 Bulk density(g/ml) 
a)untapped 
b)tapped 
 
0.631 
0.80 
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8.7. Performing the tests according to Specification Standards 
  8.7.1. Solubility study: 
         Table 8.17: Solubility of Naproxen sodium for alternate API formulation 
 
 
 
 
 
 
 
 
  
  8.7.2. Melting point: 
 Melting point values of Naproxen sodium sample was found to be in range of 
152
0
C-157
0
C. The reported melting point for Naproxen sodium was found to be 
154
0
C.  
8.7.3. Identification Tests: 
                8.7.3.1. Identification by FT-IR spectroscopy 
The FT-IR spectrum of Naproxen sodium for the API of CHARIOTEER‟S 
was shown in figure 8.12 and the interpretations of IR frequencies were showed in 
table 8.18. 
 
 
S. No Name of solvent Solubility 
 1   Distilled water    Soluble 
 2   Methanol    Soluble 
 3   Alcohol   Sparingly soluble 
 4   Acetone   Very slightly soluble 
 5  Chloroform   Insoluble 
 6  Toluene   Insoluble 
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Figure 8.12:  FT-IR spectrum of Naproxen sodium for alternate API formulation 
 Table 8.18: Characteristic IR Peaks of Naproxen sodium for alternate 
API formulation 
         Wave Number in cm 
-1
                  Characteristics 
3056.12 – 2955.82 Aromatic C-H stretching 
2745.31 – 2364.13 Overtone 
1630.47 C=O stretching 
1579.78 Presence of C-O stretching 
1478.06 -1360.78 CH3, CH2 bending 
1207.04 C-O bending 
956.52 – 620.00 CH2 bending 
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8.7.3.2. UV Method: 
    The absorption maximum for Naproxen sodium was found to be at 
272.2 nm. 
 
 
 
 
                                       
 
 
      Figure 8.13.: λ max of Naproxen sodium for alternate API formulation 
8.7.4. Specific optical rotation: 
The reported specific optical rotation was found to be at about-
15.6±0.54. Hence the value complies with that of the standard USP values.  
Table 8.19: Specific optical rotation for alternate API formulation 
 
 
  
S. No. Specific optical rotation Average Specific optical 
rotation 
1 -15.4  
-15.6±0.54 2 -15.8 
3 -16.7 
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8.7.5. Heavy metals: 
 The reported amount of Heavy metals was found to be 0.001%w/w. Hence the 
value complies with that of the standard USP.  
         Table 8.20:  Tests for heavy metals for alternate API formulation 
  
 
 
 
 
8.7.7. Loss on Drying :    
The percentage loss on drying after 3 hours was found to be as follows: 
           Table 8.21: Percentage loss on drying for alternate API formulation 
   
        
Sample passes test for loss on drying as per the limit specified in IP and USP (N.M.T. 
1%) 
 
  
S.No. Heavy metals (%w/w) Avg. percentage of Heavy 
metals. 
1 0.007  
0.001±0.00136 
 
2 0.0019 
3 0.0013 
 S. No. Percentage  LOD Average percentage LOD 
1 0.5  
0.5±0.533 
 
2 0.9 
3 0.5 
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8.7.8 Related substances Impurities: 
 
 
 
 
 
 
 
 
 
 
Figure 8.14: Related substances impurities blank for alternate API formulation 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.15: Impurities present in Naproxen sodium for alternate API 
formulation 
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Table 8.22: Impurities present in Naproxen sodium for alternate API 
formulation 
S.No Peak Name RT Area % Area 
1 Naproxen 2.517 953 0.01 
3.494 17487414 99.93 
2 Impurity-D 5.175 314 0.00 
3 Impurity-A 7.041 2948 0.02 
4 Impurity-B 9.009   
5 Impurity-C 11.5000 3953 0.02 
6  12.533 2235 0.01 
7  14.360 1543 0.01 
The related substances impurities were found to be not more than 0.01%.Hence it 
complies with USP standards. 
8.7.9. Determination of percentage purity and linearity of the drug: 
8.7.9.1. Preparation of standard graph of Naproxen sodium: 
Table 8.23: Standard graph of Naproxen sodium in pH 7.4 phosphate buffer for 
alternate API formulation 
S.No. Concentration 
(µg/ml) 
Area of the peak 
1 10 1281807 
2 20 2563618 
3 30 3845467 
4 40 5127274 
5 50 6409136 
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Figure 8.16: Standard graph of Naproxen sodium for alternate API formulation 
 
 Table 8.24: Standard graph parameters of Naproxen sodium in pH 7.4                   
phosphate buffer for alternate API formulation 
 
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope  128180.9 
3 Intercept 2219800 
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8.7.9.2. Percentage purity of drug 
The percentage purity of drug was calculated by using HPLC Chromatographic 
method. The reported percentage purity was found to be 99.7±0.12%w/w. 
                 Table 8.25:  Percentage purity of Naproxen sodium for alternate API 
formulation 
  
 
 
 
          
 
  The reported % purity for Naproxen sodium in IP is 97-102%w/w. 
8.7.9.3. Differential scanning calorimeter: 
 DSC was performed for the pure drug of Naproxen sodium for alternate 
vendor 
 
 
 
 
 
Figure 8.17: DSC thermo gram of Naproxen sodium for alternate API 
formulation 
 
S. No. Percentage purity (%) Avg. percentage 
purity (%) 
1 99.6 
 
99.7±0.12 
2 99.7 
3 99.7 
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8.8. Evaluation of Pre compression parameters for alternate API 
The blended powders of the formulations   were evaluated for angle of repose, 
loose bulk density, tapped bulk density, compressibility index and Hauser‟s ratio. The 
results of these evaluations were as follows: -  
        Table 8.26: Granulation tests for alternate API formulation 
 
 
                            *All the values were expressed as mean ± SD, n=3* 
8.8.1. Angle of repose: 
            Angle of repose was found to be at 28.7º, hence the blend was found to have 
good flowability.  
 8.8.2. Loose bulk density and tapped bulk density: 
            Bulk and tapped densities were used for the measurement of Compressibility 
index. The Loose bulk density was found to be at 0.631±0.00 g/ml and tapped bulk 
density was found to be at 0.80±0.00 g/ml 
S.No   Parameters   Result 
1 Sieve analysis  
   ASTM mesh no  
 20 25.5  
 40 60.1  
 60 78.0  
 80 82.3  
 100 84.6  
 200 92.8  
2 Moisture content* 1.86%  
3 Angle of repose* 28.7°  
4 Bulk density:*  
    Untapped 0.631±0.00 g/ml  
    Tapped 0.80±0.00 g/ml  
5 Compressibility 
index* 
13.6±0.05% 
6 Hauner‟s ratio* 1.19±0.02 
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8.8.3. Compressibility index (Carr’s index): 
 The compressibility index (%) was found to be 13.6±0.05%. The blend was 
found to have excellent flowing property as the result were found to be below 15%.  
 8.8.4. Hausner’s ratio: 
The Hausner‟s ratio was found to be 1.19±0.02.The result indicates the free flowing 
properties of the powders. 
  
8.9. Evaluation of Post compression parameters for alternate API 
 8.9.1. Appearance: 
Surface nature of tablets was observed visually and it was concluded that they did not 
show any defects such as capping, chipping and lamination.  
8.9.2. Organoleptic properties 
Odour:  Odourless  
Colour:  White or almost white  
Nature: Crystalline powder 
8.9.3. Physico-chemical characteristics:  
The physical characteristics of Naproxen sodium tablets such as thickness, 
diameter, hardness, friability, weight variation and drug content were determined and 
the results were shown in table 8.27. 
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      Table 8.27: Post compression parameters for alternate API formulation 
S.No     Parameters     Result 
 1   Disintegration time * 9  minutes 58 sec  
 2  Hardness (kg/cm2)*  9.4±0.79 
 3 Diameter (mm)* 11.5±0.01 
 4 Thickness (mm) * 4.72 ±0.01 
 5 Weight variation 
(%)*** 
302±0.15 
 6 Friability (%)* 0.34±0.01 
*All values were expressed as mean ± SD., n=3*, n=20*** 
8.9.4. Dimension (Thickness and Diameter): 
 The diameter of the tablets was found to be 11.5±0.01 mm to and thickness 
was found to be 4.72 ±0.01 mm. 
8.9.5. Tablet hardness:  
 The hardness of tablets was found to be 9.4± 0.79 kg/cm
2
. This indicates good 
mechanical strength of tablet. 
8.9.6 Percentage friability: 
Percentage friability for the formulation was found to be 0.34±0.01 %. This 
indicates good handling property of the prepared matrix tablet. 
 
 8.9.7 Weight variation: 
A tablet is designed to contain a specific amount of drug. When the average 
weight of the tablet is 300 mg, the pharmacopoeia limit for percentage deviation is ± 
5%. The weight variation for the tablets was found to be 302±0.15, and hence 
formulation complied with the test for weight variation according to the 
pharmacopoeial specifications IP. 
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8.9.8. Drug content: 
 The drug content for the formulation was found to be 99.7 ± 0.12% w/w, 
which was within the specified limit as per IP .The values are shown in Table 8.25. 
8.9.9 In-vitro dissolution studies: 
                   Table 8.28: Dissolution profile of the formulation for alternate API 
formulation 
 
  S. No Time in 
minutes* 
Percentage drug 
released 
    1          5       27.6 
    2         10       45.0  
    3         15       77 .5 
    4         30       85 .2 
    5         45       92.0  
    6         60       99.2 
*All values were expressed as mean ±SD, n=3* 
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 Figure 8.18: In-vitro drug released profile of formulation for alternate API 
formulation 
 In-vitro dissolution studies of formulation were carried out in 7.4 phosphate 
buffer medium and % of drug release was calculated. The formulation was kept for 60 
min. It was found that the formulation meets the standard limits. 
.                       Table 8.29: Time of in-vitro drug release of t25,t 50, t90 values for 
alternate API formulation 
S. No Time in 
min 
 t25  t 50  t90 
1 5 4.166 8.33 15 
2 10 4.464 8.928 16.07 
3 15 4.62 9.25 16.66 
4 30 7.57 15.15 27.27 
5 45 11.25 22.5 40.5 
6 60 14.56 29.412 52.42 
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8.10. Stability studies for alternate API 
After exposure to accelerated stability conditions the formulation was 
analyzed for various parameters. The results are shown in Table 8.30 and Figures 
8.19, 8.20 and 8.21. 
Table 8.30: Stability studies of Alternate API Formulation. 
S. No Parameters Initial 1
st
 month 2
nd
 month 3
rd
 month 
1 Description White 
coloured 
round shaped 
coated tablets 
White 
coloured 
round shaped 
coated tablets 
White 
coloured 
round 
shaped 
coated 
tablets 
White 
coloured 
round 
shaped 
coated 
tablets 
2 Disintegration* 
(min) 
9 min 58sec 9 min 55 sec 9 min 42 
sec 
9 min 39sec 
3 Hardness* 
(kg/cm²) 
9.4±0.79 9.4±0.1 9.1±0.1 8.9±0.2 
4 Assay* 
(%w/w) 
99.7±0.12 99.6±0.1 99.54±0.1 99.1±0.17 
5 Dissolution* 
(%) 
99.2±0.1      99.0±0.05 98.8±0.15 98.6±0.1 
                          *All the values were expressed as mean± S.D., n=3. 
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Figure 8.19: Comparison for hardness of before and after stability studies. 
 
 
 
Figure.8.20: Comparison for disintegration of before and after stability studies  
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Figure: 8.21: Comparison for drug content profile of before and 
after stability studies   
 
 
 
Figure.8.21: Comparison for dissolution profile of before and after 
stability studies    
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From the above studies there was no significance difference between the 
evaluated data from initial and after stability studies and all the values were found in 
worth accepting limits. The formulation was showed adequate physical stability at 
40
o
C±2
o
C at 75±5% relative humidity.   
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COMPARISION OF DISSOLUTION PROFILES OF BOTH THE 
API’S (APPROVED (REDDY’S) AND ALTERNATIVE 
(CHARIOTEER’S)  
 
Figure.8.22: Comparison of dissolution profiles of both the API’S 
 
The amount of percentage drug release of both the API sources was compared 
and was found to be similar. 
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8.11. Comparison of certificate of analysis for both the API’S 
Table 8.31: Comparison of CERTIFICATE Of Analysis for both the API’S. 
S.No Test REDDY’S CHARIOTEER’S 
1 Description White crystalline 
powder 
White crystalline 
powder 
2 Specific optical rotation -16.76 -15.6 
3 Assay (%w/w) 99.8. 99.7 
4 Untapped density (g/ml) 0.632 0.631 
5 Tapped density (g/ml) 0.79 0.80 
6 Loss on drying (%) Not more 
than1.0%w/w 
Not more 
than1.0%w/w 
7 Related substances 
impurities (%) 
Not more than 0.1% Not more than 0.1% 
All the   above performed tests complies with the specification standards and 
the results obtained by both the approved API source i.e, REDDY‟S and also the 
alternate API source i.e. CHARIOTER‟S were found to be similar or almost 
equivalent Naproxen sodium was been formulated and marketed using the API of 
approved vendor i.e. REDDY‟S LTD by the GRANULES INDIA LTD. 
As the approved API from REDDY‟S was not sufficient due to much demand 
for the drug Naproxen sodium in marketing field. An alternate vendor i. e, 
CHARIOTEER was proposed  
According to regulatory point of view an alternate vendor for Active 
pharmaceutical ingredient   can be approved if the specification standards and 
dissolution profile was same as compared with that of the already approved API 
according to the Alternate vendor guideline. 
Hence the comparison for both the specification standards and percentage drug 
release was done for approved vendor (REDDY‟S) and alternate vendor 
(CHARIOTEER).Hence further formulation of the drug Naproxen sodium can be 
carried out using the alternate API source. 
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8.12. FORMULATION of Naproxen sodium using  
Approved Alternate API (CHARIOTEER’S) 
8.12 Composition of Naproxen sodium Immediate tablets using Approved 
Alternate Vendor. 
Table 8.32: Composition of Naproxen sodium using approved alternate API 
S.No Ingredients (mg)                                Formulation  
F1 F2 F3 F4 F5 F6 
1 Naproxen sodium 220 220 220 220 220 220 
2 Microcrystalline cellulose - 
 
- 
 
44.0 
 
39.0 45.0 42.0 
3 Corn starch 73.0 72.7 27.6 26.6 20.6 23.6 
4 Sodium  
starch glycolate 
4.6 4.9 6 6 6 6 
5 Water - - - qs qs qs 
6 Povidone - - - 6 6 6 
7 Stearic acid 2.4 2.4 2.4 2.4 2.4 2.4 
8 Total 300 300 300 300 300 300 
                         *All the ingredients were expressed as mg per tablet. 
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8.13. Physico chemical characteristics of powder blends: 
The blended powders of different formulations were evaluated for angle of 
repose, loose bulk density, tapped bulk density, compressibility index and Hauser‟s 
ratio. The results of these evaluations were as follows:  
              Table 8.33:  Physico chemical characteristics of Naproxen sodium 
 
FORMUL
ATION 
CODE 
 
 
BULK 
DENSITY* 
 (g/ml) 
 
 
TAPPED 
DENSITY* 
(g/ml) 
 
 
COMPRESSI
BILITY 
INDEX* 
(%) 
 
HAUSNER’S 
RATIO* 
 
ANGLE OF 
REPOSE* 
(º) 
F1 0.641±0.00 0.825±0.00 13.41±0.03 1.17±0.01 28.26±0.15 
F2 0.655±0.00 0.725±0.01 12.27±0.05 1.17±0.00 26.34±0.14 
F3 0.649±0.01 0.798±0.00 13.47±0.04 1.25±0.01 25.63±0.06 
F4 0.631±0.01 0.587±0.01 12.30±0.03 1.17±0.02 25.31±0.24 
F5 0.634±0.01 0.819±0.02 13.56±0.02 1.23±0.00 26.61±0.28 
F6 0.648±0.00 0.712±0.01 12.77±0.04 1.29±0.01 27.59±0.17 
 *All values are expressed as mean ±S.D., n=3. 
8.12.2.1. Angle of repose: 
            Angle of repose ranged from 25.31±0.24 to 28.26±0.15.Hence the blend was 
found to have good flowability.  
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8.12.2.2. Loose bulk density and tapped bulk density: 
            Bulk and tapped densities are used for the measurement of Compressibility 
index. The LBD and TBD ranged from 0.631± 0.01 to 0.655± 0.00 g/ml, and       
0.587±0.001 to 0.825± 0.00 g/ml respectively.  
 
8.12.2.3. Compressibility index (Carr’s index): 
 The compressibility index (%) ranged from 12.27± 0.05 to 13.56± 0.02. The 
blend was found to have good flowing property as the result were found to be below 
15%. 
 
 8.12.2.4. Hausner’s ratio: 
 
The Hausner‟s ratio ranged from 1.17± 0.00 to 1.29 ± 0.01.The result indicates 
the free flowing properties of the powders. 
 
8.14. EVALUATION OF TABLETS: 
8.13.1. Appearance 
            The tablets were observed visually and did not show any defects such as 
capping, chipping and lamination. 
8.13.2. Physicochemical characteristics: 
             The physical characteristics of Naproxen sodium (F1 to F6) such as thickness, 
diameter, hardness, friability, weight variation and drug content were determined and 
results of the formulations (F1 to F6) found to be within the limits specified in official 
books. 
 
Study and Evaluate to Propose An Alternate API  Results & Discussion 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 127 
 
 
Table 8.34: Evaluation of Naproxen sodium tablets 
 
CODE 
Diameter* 
(mm) 
Thickness* 
(mm) 
Hardness* 
(kg/cm
2
) 
Friability* 
(%) 
Weight 
variation* 
(mg) 
Drug 
content 
*(%w/w) 
F1 13.20±0.166 4.6±0.152 8.2±0.115 0.44±0.015 301±0.020 99.50±0.26 
F2 13.36±0.035 4.2±0.152 8.4±0.115 0.42±0.01 303±0.019 98.42±0.36 
F3 13.35±0.015 4.4±0.1 8.1±0.0577 0.29±0.02 298±0.020 95.88±0.48 
F4 13.31±0.02 4.7±0.1 8.6±0.230 0.54±0.025 299±0,022 99.2±0.25 
F5 13.1±0.08 4.6±0.1 9.2±0.115 0.38±0.03 301±0.026 99.9±0.32 
F6 13.36±0.025 4.7±0.1 9.8±0.34 0.59±0.02 303±0.022 99.2±0.26 
                                  *All values are expressed as mean ±S.D. n=3. 
8.13.2.1. Dimension (Thickness and Diameter) 
Thickness and diameter specifications may be set on an individual product 
basis. There were no marked variations in the thickness and diameter of tablets within 
each formulation indicating uniform behaviour of granules throughout the 
compression process. The diameter of the tablets of all formulations were found to be 
ranged between 13.1±0.08 to 13.36±0.035 mm and thickness ranged between 
4.2±0.15 to 4.7±0.1mm 
8.13.2.2. Tablet Hardness:  
A difference in tablet hardness reflects difference in tablet density and 
porosity. Which in turn are supposed to result in different release pattern of the drug 
by affecting the rate of penetration of dissolution fluid at the surface of the tablet and 
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formation of gel barrier. The hardness of tablets was found to be in the range of 
8.1±0.057 kg/cm
2
 to 9.8±0.34 kg/cm
2
. This indicates good tablet strength.  
8.13.2.3. Percentage Friability: 
Percentage friability of all the formulations was found between 0.29±0.02 to 
0.59±0.02 %. This indicated good handling property of the prepared tablet. 
 
8.13.2.4. Weight Variation: 
A tablet is designed to contain a specific amount of drug. When the average 
mass of the tablet is 300 mg the pharmacopoeial limit for percentage deviation is 
±5%. The weight variation for the tablets was found between 298±0.020 to 303±0.022 
%. 
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8.13.3. In-vitro disintegration studies: 
           Table 8.35: Disintegration time of Naproxen sodium formulation. 
CODE Disintegration time(min)* 
F1 11.15±0.104 
F2 12.56±0.280 
F3 13.02±0.064 
F4 12.24±0.450 
F5              10.5±0.30 
F6 11.88±0.160 
             *All values are expressed as mean ±S.D. n=3*. 
     Figure 8.23: Comparison of Disintegration time of   formulations(F1-F6) 
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8.13.4. In-Vitro Dissolution Studies: 
 
Table 8.36:  In-Vitro drug released data of formulation F1 
S.No Dissolution  
medium 
Time (min) *Percentage drug 
released 
1  
 
7.4 phosphate 
buffer 
0 0.00 
2 5 27.4±0.95 
3 10 54.3±1.24 
4 15 66.0±0.15 
5 30 76.8±0.45 
6 45 82.5±0.90 
7 60 89.2±0.79 
*All values are expressed as mean ±S.D. n=3*. 
 
 
 
Figure 8.24:  In-Vitro drug released profile of formulation F1. 
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Table 8.37: In-Vitro drug released data of formulation F2. 
S.No Dissolution 
Medium 
Time (min) *Percentage 
drug released 
       1  
 
  7.4 Phosphate 
buffer 
0 0.00 
2 5 29.8±0.61 
3 10 54.1±0.32 
4 15   63.3.0±1.47 
5 30    79.0±0.50 
6 45 87.0±1.32 
7 60 90.2±0.1 
         *All values are expressed as mean ±S.D. n=3*. 
 
 
 
Figure 8.25:  In-Vitro drug release profile of formulation F2 
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Table 8.38: In-Vitro drug released data of formulation F3. 
S.No Dissolution 
medium  
Time (min) *Percentage 
drug released 
1  
 
7.4 Phosphate 
buffer 
0 0.00 
2 5 24.2±0.87 
3 10 47.1±0.15 
4 15 68.0±0.26 
5 30 87.5±0.87 
6 45 91.0±0.72 
7 60 93.5±0.5 
                           *All values are expressed as mean ±S.D., n=3*. 
 
 
 
Figure 8.26:  In-Vitro drug release profile of formulation F3 
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Table 8.39: In-Vitro drug released data of formulation F4. 
S.No Dissolution  
medium 
Time (min) *Percentage 
drug released 
 
1  
 
7.4 
Phosphate 
buffer 
0 0.00 
2 5 31.3±0.20 
3 10 50.8±0.64 
4 15 74.6±0.41 
5 30 86.6±0.55 
6 45 90.2±0.25 
7 60 95.4±0.70 
              *All values are expressed as mean ± S.D., n=3*. 
 
 
 
 
Figure 8.27: In-Vitro drug release profile of formulation F4. 
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Table 8.40: In-Vitro drug released data of formulation F5. 
S.No Dissolution 
medium 
Time (min) 
*Percentage 
drug released 
1  
 
7.4 
Phosphate 
buffer 
0 0.00 
2 5       34.3±0.30 
3 10 59.8±0.52 
4 15 76.5±0.65 
5 30 88.8±0.75 
6 45 95.2±0.50 
7 60 99.1±0.26 
                          *All values are expressed as mean ± S.D., n=3*. 
 
 
 
 
Figure 8.28: In-Vitro drug release profile of formulation F5. 
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Table 8.41: In-Vitro drug released data of formulation F6. 
S.No Dissolution 
medium 
Time (min) *Percentage 
drug released 
 
1  
 
7.4 phosphate 
buffer 
 
 
0 0.00 
2 5 27.3±0.15 
3 10 51.8±0.91 
4 15 68.2±1.66 
5 30 79.1±0.41 
6 45 80.2±0.65 
 60 90.5±0.66 
                *All values are expressed as mean ± S.D., n=3*. 
 
 
Figure 8.29: In-Vitro drug release profile of formulation F6. 
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Figure 8.30: Comparison of In-Vitro drug released profile of formulations F1-F6.       
   According to In-Vitro drug released data of dissolution studies of 
formulation F1&F2 &F3 prepared by direct compression method were found to be 
89.2%, 90.2% and 93.5%respectively. The drug released data of formulations 
containing microcrystalline cellulose as diluent were found to be 95.4%, 99.1% and 
90.5% respectively. On increasing the concentration of diluents microcrystalline 
cellulose there was increase in the % drug release. Based on above drug released data 
formulation (F5) was showed a highest In-Vitro released profile among the all 
formulations. 
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Table.8.42: Percentage drug released t25, t50 and t90. 
Formulations Percentage drug released (time in min) 
          t25                  t50         t90 
F1 5.48 9.20 60.53 
F2 4.19 9.24 59.86 
F3 5.16 10.61 57.75 
F4 3.99 8.44 56.60 
F5 3.644 8.36 54.49 
F6 4.62 8.44 59.8 
 
 
 
Figure 8.31: Percentage drug released of t25, t50, t90 values. 
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8.15. Stability studies: 
 After exposure to accelerated stability conditions the formulation was 
analyzed for various parameters. The results are shown in table 8.43. 
 
Table 8.43:  Stability study data of optimized formulation (F5).  
Parameter Initials 1
st
 Month 2
nd
 Month 3 
rd 
Month 
Description 
 
White coloured 
round shaped 
coated tablets 
Complies Complies Complies 
Disintegration* 
(min) 
10 min 5 sec 10 min 2 
sec 
9 min 95 
sec 
9min 68 sec 
Hardness* 
(kg/cm
2
) 
    9.2±0.115    9.0±0.11   8.8±0.1   8.6±0.1 
Assay*(%w/w)   99.9±0.32   99.6±0.1   99.4±0.1   99.2±0.1 
Dissolution* 
(%) 
  99.1±0.26   98.8±0.15   98.5±0.1   98.1±0.15 
                  *All values are expressed as mean ± S.D., n=3*. 
No major difference was found between evaluated parameters before and after 
stability studies and all are in acceptable limits. The tablets showed satisfactory 
physical stability at 40˚C±2˚C at 75 % RH±5%RH. 
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        Figure 8.32: Comparison for disintegration before and after stability studies. 
 
 
Figure 8.33: Comparison for hardness before and after stability studies.
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Figure 8.34: Comparison for Assay of before and after stability studies  
 
Figure 8.35: Comparison for percentage drug released of before and after 
stability studies
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  The specification standards and dissolution profile was compared for the drug 
Naproxen sodium for both approved vendor (REDDY‟S) and alternate vendor 
(CHARIOTEER)    and was found to be similar. 
Hence the alternate vendor API i.e charioteer can be approved for formulation 
and further marketing. A Successful immediate drug delivery system was prepared 
with immediate release mechanism that gives immediate on set of action, by using 
both the approved and alternate API source. 
Naproxen sodium posses Longer half life and maximum water solubility; 
hence it was a good candidate for Immediate release drug delivery system. The 
identification of drug was carried out by IR, UV and melting point. 
  The physicochemical parameters such as appearance, solubility study and loss 
on drying were performed by suitable methods for both the formulations. 
  The analytical profile of drug was evaluated for development of standard 
curve and percentage purity of drug. 
  Compatibility of drug was done by performing DSC study. 
 It was concluded that results obtained by both the API‟S were found to be 
similar. Impurities present in the drug were found unaltered in the HPLC 
chromatogram and peaks in the DSC thermogram of drug disintegrant physical 
mixture. The powder blend was prepared by blending various ingredients in mortar 
and pestle for 20 min and evaluated for bulk density, tapped density, carr‟s index, 
         SUMMARY   AND   CONCLUSION 
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Hausner‟s ratio angle of repose.Immediate release tablet of Naproxen sodium was 
obtained by wet granulation method for both the API formulations. 
Formulations prepared composed of   povidone, sodium starch glycolate as 
disintegrants, and microcrystalline cellulose as diluents. 
Hence by comparing  the specification standards i.e certificate of analysis of 
both the approved API source , the certificate of analysis of alternate API source and 
dissolution profiles of both the API sources it can be concluded that the results of  
Alternate API source ie CHARIOTER  is equivalent with that of the Approved API 
source. 
According to Alternate Vendor Guideline in regulatory point of view an 
alternate   vendor for Active pharmaceutical ingredient can be approved if the 
specification standards and dissolution profile was same as compared with that of the 
already approved API source. 
Hence the formulation of Naproxen sodium can be done by using the alternate 
API source i.e, CHARIOTER. 
Further formulation was carried out using the API of APPROVED 
ALTERNATE source and 6 formulations were carried out. 
 Out of the 6 formulations first 3 formulations were done using direct 
compression method and next 3 formulations were done by wet granulation method. 
  Formulations were prepared using same excipients and evaluation was carried 
out.  
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The performance with respect to disintegration time and % drug rele59ased F5 
was selected as the best formulation as it showed its disintegration time within 10 
minutes and percentage drug released at 99.9% at 60 minutes time interval. 
According to stability it was found that there was no significant change in 
hardness, drug content and In-vitro dissolution of optimised formulation F5. 
 
  
 
 
FUTURE 
PROSPECTS.... 
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As the alternate vendor qualification was found to be successful, the selection of more 
alternate vendor‟s can be done in order to acquire surplus supply of API sources for the drugs 
that are in demand. 
 In the field of immediate release, there are many obstacles that need to be overcome 
in order to be able to claim true immediate release. Considering the advantages for improved 
delivery of drugs further clinical studies are needed to access the utility of this system for 
patients suffering from acute gout, musculo skeletal complaints. 
 This dosage forms holds promise for further systems. In-Vitro-In-Vivo correlation 
(IVIVC) will serve as a means of modelling the human organism and of gaining a better 
understanding of drug absorption and its dependence on In-Vitro release process.  
  Convincing results of clinical studies have yet to be obtained for a Immediate release 
system that displays the necessary performance behaviour and which is retained in the fasted 
stomach of humans for a sensible period of time after dosing. Furthermore, the system will 
need to release the drug with in short period of time. 
 Once the technology is fully accepted, these systems will probably increase with new 
pipeline drugs that need enhancement to their bioavailability. 
Finally while the increasing the drug release profile there by immediate on set of 
action has been a major aim of pharmaceutical research and development in the past two 
decades, the increasing on set of action by Immediate release profiles could be the focus of 
the next two decades and might result in the availability of new products with new 
therapeutic possibilities and substantial benefits for patients. 
 FUTURE PROSPECTORS 
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